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Abstract 
Introduction: Recent research suggests an association between environmental 
cadmium exposure and increased risk of, and death from, cardiovascular disease, the 
number one cause of mortality in Australia and worldwide. However, the research to 
date is neither comprehensive nor have there been any studies conducted on an 
Australian population. This study identified whether increasing concentrations of 
urinary cadmium in elderly West Australian women was associated with an increased 
odds of incidence of, and deaths from CVD, as well as all-cause mortality. 
Method: Cadmium excretion was measured in urine samples collected at baseline 
(1998) from 1359 women from Perth who were at least 70 years old. Samples were 
analysed for cadmium concentrations using Inductively Coupled Plasma – Mass 
Spectrometer. Urine samples were also analysed for creatinine, and specific gravity. 
Morbidity and mortality data from the Western Australian Data Linkage System 
(WADLS) and the Western Australian Hospital Morbidity Data System (WAHMDS) 
for the follow-up period (1998-2013), which was collected by the Bone and Vascular 
Research Group were used for this study.  Odds ratios (ORs) were calculated for CVD 
and all-cause mortality endpoints. Subsequent calculations of hazard ratios (HR) were 
completed for those endpoints, which were significantly associated with urinary 
cadmium in the logistic regressions. All analyses initially included the overall 
population, however, to identify the influence of smoking on risk, the models were 
repeated with stratification of the population by smoking history. 
Results: The median (IQR) concentration of cadmium in urine for the sample 
population was 0.180 (0.09-0.32) µg/L. Logistic regression analyses identified 
statistically significant relationships between six of the outcome variables and 
increasing urinary cadmium concentrations. In the total population an increased urinary 
cadmium was associated with an increased odds of atherosclerotic vascular disease 
death (OR = 1.156, 95% CI = 1.015-1.315), multiple causes of death heart failure (HF) 
(OR = 1.414, 95% CI = 1.141-1.751), HF event (OR = 1.181, 95% CI = 1.002-1.391), 
and those with urinary cadmium concentrations > 0.255 µg/L had an OR of 2.769 (95% 
CI = 1.439-5.327) for multiple causes of death HF when compared to the participants in 
the lowest cadmium concentration tertile (≤ 0.155 µg/L). When stratified by smoking 
history, never smokers with increasing cadmium concentrations were at greater odds of 
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multiple causes of death HF (OR = 1.304, 95% CI = 1.026-1.657) and peripheral arterial 
disease (PAD) event (OR = 2.260, 95% CI = 1.011-5.053), whilst participants with 
cadmium concentrations > 0.255 µg/L reported OR’s of 2.422 (95% CI = 1.149-5.327) 
and 2.26 (95% CI = 1.011-5.053) for multiple causes of death HF and PAD event, 
respectively, when compared to participants with concentrations ≤ 0.155 µg/L. In ever 
smokers, participants with increasing urinary cadmium concentrations were at increased 
odds of all-cause mortality (OR = 1.423, 95% CI = 1.153-1.756), HF event (OR = 
1.627, 95% CI = 1.089-2.341) and PAD event (OR = 2.639, 95% CI = 1.101-6.327). 
Ever smokers with cadmium concentrations > 0.255 µg/L were at increased odds of all-
cause mortality (OR = 2.105, 95% CI = 1.190-3.411), HF event (OR 4.823, 95% CI = 
1.295-17.966) and PAD event (OR = 2.639, 95% CI = 1.101-6.327) compared to those 
with concentrations ≤ 0.155 µg/L. In the survival analysis, ever smokers with cadmium 
concentrations > 0.255 µg/L reported a hazard ratio (HR) of 1.683 (95% CI = 1.155-
2.451) for time until death resulting in all-cause mortality, when compared to 
participants with the lowest cadmium concentrations (≤ 0.155 µg/L). All models were 
adjusted for demographic and cardiovascular risk factors.  
Conclusion: Low-level environmental exposure to cadmium was associated with five 
CVD endpoints as well as all-cause mortality. When stratified by smoking history, those 
who had never smoked were at significantly greater odds of multiple causes of death 
heart failure and peripheral arterial disease event. In ever smokers, participants with 
higher cadmium concentrations were at greater odds of all-cause mortality, heart failure 
event and peripheral arterial disease event. This research indicates that low 
environmental exposure to cadmium may be a risk factor in mortality and CVD in 
Australian populations. More research in different Australian populations to confirm 
these findings is required. 
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Introduction 
Cadmium is a widespread heavy metal used in several different industrial and 
agricultural processes, which has been shown to be associated with many serious 
chronic diseases (Nawrot et al., 2010). Exposure of the general population to cadmium 
is largely through smoking and diet, with diet being the main source of cadmium in 
never smokers (Nawrot et al., 2010). For decades it has been shown that occupational 
exposure to cadmium has negative impacts on health (Agency for Toxic Substances and 
Disease Registry, 2012), however, it is only in the past 10-15 years that researchers 
have conducted and identified relationships between environmental exposure to 
cadmium and increased risk of disease. Relationships with decreased bone mineral 
density (Gallagher, Kovach, & Meliker, 2008), impaired kidney function (Olsson et al., 
2002), various cancers (Åkesson et al., 2012; McElroy, Shafer, Trentham-Dietz, 
Hampton, & Newcomb, 2006) and all-cause mortality (Menke, Muntner, Silbergeld, 
Platz, & Guallar, 2009) have all been identified as being associated with cadmium 
exposure. However, so far there has been limited attention paid to the potential role of 
cadmium in cardiovascular disease (CVD). A small number of studies have been 
conducted internationally and have found an association between cadmium exposure 
and the incidence of CVD, however, most of these studies were cross-sectional (Everett 
& Frithsen, 2008; Julin, Bergkvist, Wolk, & Akesson, 2013; Navas-Acien et al., 2005; 
Peters, Perlstein, Perry, McNeely, & Weuve, 2010), with only a few longitudinal studies 
conducted to date (Menke et al., 2009; Tellez-Plaza, Guallar, Howard, et al., 2013).  
Therefore, it is not possible to infer causation and the relationship between cadmium 
and CVD requires confirmation in other populations. 
To the researcher’s knowledge there has been no research to date, which has examined 
the relationship between cadmium exposure and CVD in an Australian population, 
although there have been a few studies that have analysed cadmium exposure in 
vulnerable groups within the Australian population. Recently, cadmium exposure has 
been measured in pregnant women (Hinwood et al., 2013) children (Callan, Winters, 
Barton, Boyce, & Hinwood, 2012) and older women (Callan, Devine, Qi, Ng, & 
Hinwood, 2015). These studies suggest exposure in Australia is at a level at which 
health risks may occur such as decreased bone density, so further investigation of the 
potential health effects associated with cadmium exposure is required. Like many 
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developed countries, Australia’s population is ageing, making health and the diseases 
associated with older people an important area for further research. 
According to the Australian Bureau of Statistics [ABS] (2014) and the World Health 
Organization [WHO] (2013), the number one cause of mortality in Australia and 
globally is CVD. More specifically, 17.3 million people worldwide died in 2008 from 
CVD, representing 30% of all deaths globally that year (WHO, 2013), and one in three 
Australian deaths in 2009 were attributed CVD (AIHW, 2014). These statistics 
highlight the need for research into the risk factors for CVD incidence and mortality. 
Given that an association between cadmium exposure and CVD has been identified in 
international studies (Everett & Frithsen, 2008; Navas-Acien et al., 2005; Peters et al., 
2010; Tellez-Plaza, Guallar, Howard, et al., 2013), further research in this area is 
warranted to confirm these findings in the Australian population. 
The Bone and Vascular Research Group (BVRG) of the School of Medicine and 
Pharmacology, the University of Western Australia, QEII, has collected longitudinal 
data from 1500 elderly women through three sequential studies between 1998 and 2013, 
including collection of urine samples at baseline and morbidity and mortality data for 15 
years. These data were used to examine the association between cadmium exposure and 
the incidence of CVD and all-cause mortality in elderly West Australian women.  
These data were used to address the following research question: 
Research question 
In non-occupationally exposed elderly West Australian women, are increasing urinary 
cadmium concentrations associated with incidence of, and deaths from cardiovascular 
disease, or all-cause mortality?   
Hypothesis 
Environmental cadmium exposure is associated with the incidence of, and death from 
CVD as well as all-cause mortality, in elderly women in Perth.   
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Literature Review 
Sources of Cadmium Exposure 
Cadmium is a widespread pollutant and toxicant that occurs naturally in ores together 
with lead, copper and zinc (Järup, 2003). Humans are exposed to the heavy metal 
through industrial processes, such as smelting, welding, battery manufacture and paint 
production, and agricultural processes, such as fertilisers, both of which contribute to 
increasing cadmium concentrations in the environment (Mann, Rate, & Gilkes, 2002; 
Nawrot et al., 2010). In terms of the environmental exposure, Järup (2003) and Nawrot 
et al. (2010) state that in non-occupationally exposed individuals, who reside in non-
contaminated areas, up to 90% of exposure is through diet. However, this amount is 
only representative for those who have never been smokers and those exposed to little 
environmental tobacco smoke, as cigarette smoke contains high concentrations 
cadmium (Nawrot et al., 2010).  
Dietary Cadmium Exposure 
The dietary intake of cadmium varies between populations as it is influenced by the 
intake habits of that population and the concentration of cadmium in the soil from 
which the food was grown (Bester, Lobnik, Erzen, Kastelec, & Zupan, 2013; Dorris, 
Atieh, & Gupta, 2002). Usually, the bioavailability of cadmium is between 3-5%, 
however, intakes of iron, calcium and protein influence the rate of absorption (European 
Food Safety Authority [EFSA], 2009; Nordberg, Nogawa, Nordberg, & Friberg, 2007). 
The two largest contributors to human exposure are vegetables and cereals, although 
these do not have the highest concentrations of cadmium (Callan, Hinwood, & Devine, 
2014) they are consumed in large amounts (Nawrot et al., 2010). These foods leach 
cadmium from soil, with some vegetables, such as leafy vegetables (Bagdatlioglu, 
Nergiz, & Ergonul, 2010), being better at absorbing cadmium than others (Nawrot et al., 
2010). Other foods that are rich in cadmium include molluscs, crustaceans and 
mammalian kidney and liver (WHO, 2010).   
Metabolism and Excretion of Cadmium 
Cadmium ingested is absorbed through the gastrointestinal tract and bioaccumulates in 
the body tissues, kidneys and liver (Julin et al., 2013; Messner & Bernhard, 2010). To 
assess exposure to cadmium, urinary analysis was used as it is the recognised and 
 Association between Cadmium and CVD  
 
4 
accepted measure of long-term exposure (Lauwerys & Hoet, 2001). Cadmium has a 
half-life of 15 to 30 years in the kidney, compared to cadmium in blood, where it is only 
stored for three months (Nawrot et al., 2010). An Australian study by Hinwood et al. 
(2013), examined 173 pregnant women and found that 35% had a urinary cadmium 
concentration of greater than 1 µg/g creatinine, putting them at an increased risk of 
health effects resulting from exposure. Callan et al. (2015) investigated cadmium 
exposure in Australian women aged 50 and over and found that concentrations of 
cadmium in urine were lower than those in the younger women in the Hinwood et al. 
(2013) study, however, an association between urinary cadmium and decreased bone 
mineral density was identified. Higher concentrations in Hinwood et al. (2013) may be 
explained by the lower iron status in pregnant women and the increased requirement for 
iron by the foetus, which has been shown to increase absorption and retention of 
cadmium (Akesson et al., 2002). 
Cardiovascular Disease  
CVD describes any condition or disease associated with the heart and blood vessels and 
it is hypothesized that atherosclerosis is the main cause of CVD (Hall & Guyton, 2011; 
Messner & Bernhard, 2010). Atherosclerosis is the build-up of degenerative material in 
the inner wall of the arteries forming plaques (Messner & Bernhard, 2010). Since 1996 
CVD has been classified as a national health priority area in Australia due to its burden 
on the community and government (AIHW, 2013). In 2008-09 Australian health care 
expenditure for CVD was 7.7 billion dollars (12% of total health expenditure) making it 
the most expensive disease group and as such it remains an important area of research 
(AIHW, 2014b). Although the total incidence of CVD mortality has decreased in the 
past decade, it was still the number one cause of mortality in Australia in 2012 (AIHW, 
2014b). Further, in 2007-2008, an estimated one in six (3.4 million) Australians 
reported having at least one long-term CVD (ABS, 2014). 
In order to complete the research in the time allowed for honours, the scope of the study 
must be very concise. Therefore, this study has only focused on the four CVD that are 
most prevalent in the Australian population (AIHW, 2014a). These four diseases are: 
coronary heart disease (CHD), stroke or cerebrovascular accident (CVA), heart failure 
(HF) and peripheral arterial disease (PAD), which are collectively known as 
atherosclerotic vascular disease (ASVD) (Hackam & Anand, 2003; Haskell et al., 
2003), which is also analysed.  
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According to an AIHW report, in 2007 CHD accounted for almost half (49%) of the 
CVD deaths in Australia (2011). CHD refers to a condition where a lack of oxygenated 
blood reaches the cardiac muscle. It is usually as a result of a blockage in the coronary 
arteries and if left untreated, cardiac muscle cells starve and die (Hall & Guyton, 2011). 
Stroke, or CVA is the second most common cause of cardiovascular death and occurs 
when the artery supplying blood to the brain is suddenly blocked and the tissue becomes 
deoxygenated and can die if left untreated (AIHW, 2011; Hall & Guyton, 2011). For the 
purposes of this study we have only considered ischaemic strokes. HF is a complex 
outcome of vascular disease possibly related to increasing arterial stiffness due to 
arteriosclerosis, which results in a failure of the heart to pump sufficient blood to the 
body in order to maintain normal bodily functions (Hall & Guyton, 2011). If the 
peripheral arteries suddenly become blocked, which may be due to plaque build-up, and 
the peripheries become hypoxic, it is referred to as PAD (Hall & Guyton, 2011). ASVD 
occurs as a result of partial blockages in the arteries causing angina (Hackam & Anand, 
2003; Haskell et al., 2003). 
Cadmium and Cardiovascular Disease 
In recent decades there have been a number of animal studies undertaken to investigate 
cadmium exposure and blood pressure. Schroeder, Balassa, and Vinton (1965) orally 
fed rats 0.35 mg Cd/kg bw/day for 3 years and concluded that those who consumed 
cadmium were more likely to have enlarged and atherosclerotic hearts. An increase in 
ventricular mass and hypertension formation was shown in a study of rats conducted by 
Tomera and Harakal (1988). Several other animal studies have shown an increase in 
blood pressure following cadmium exposure (Akahori et al., 1994; Carmignani & 
Boscolo, 1984; Perry, Erlanger, Gustafsson, & Perry, 1989). In contrast, Fingerle, 
Fischer, and Classen (1982) and Kotsonis and Klaassen (1978) both found that feeding 
a cadmium rich diet to rats did not result in a change in blood pressure. In conclusion, 
the animal studies have produced conflicting evidence. However, as most of the animal 
studies were conducted using intakes of cadmium much greater than any potential 
human dietary intake, making comparisons between animal studies and the human 
population difficult. 
The potential role of cadmium in CVD and related outcomes has not been extensively 
studied in humans. In a cross-sectional study undertaken by Navas-Acien et al. (2005) 
using a sample (N = 790, age ≥ 40 years) from the U.S. National Health and Nutrition 
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Examination Survey (NHANES) population, an association between cadmium exposure 
and prevalent peripheral arterial disease (PAD) was found. The authors reported that 
individuals with PAD had a 36% higher urinary cadmium concentration and, when also 
adjusted for smoking status, the association remained significant decreasing only 
slightly. Furthermore, another U.S. study by Everett and Frithsen (2008), also cross-
sectional and using a sample from the NHANES cohort (N = 4912, age 45-79), 
concluded that those with a urinary cadmium concentration of ≥0.88 µg/g creatinine 
were 1.86 times more likely to have a myocardial infarction (95% CI = 1.26-2.75), 
compared with those with a urinary cadmium concentration of less than 0.43 µg/g 
creatinine, after adjustment for pack-years of smoking, Framingham risk score, family 
history and diabetic status. Researchers of a third cross-sectional study using a 
NHANES sample (N = 12,049, age ≥ 30 years) found that a 50% increase in the urinary 
cadmium concentration was associated with a 9% increase in prevalent stroke and 12% 
increase in prevalent HF when adjusted for demographic and cardiovascular risks 
(Peters et al., 2010). 
One of the few longitudinal studies investigating environmental cadmium exposure and 
CVD risk was conducted by Tellez-Plaza, Guallar, Howard, et al. (2013). The 
researchers sampled a population of American Indian men and women (N = 3348) 
between 45 and 74 years and concluded that those with a urinary cadmium 
concentration > 1.45 µg/g were 1.48 (95% CI = 1.21-1.80) times more likely to have a 
CVD incident than individuals with a cadmium concentration of ≤ 0.61 µg/g, when 
adjusted demographic and cardiovascular risk factors. They were also 1.33 (95% CI = 
1.05-1.68) times more likely to have a CHD incident, when adjusted for the same 
confounders. Further, individuals with urinary cadmium concentrations of > 1.45 µg/g 
were 1.87 (95% CI = 1.34-2.60) and 1.51  (95% CI = 1.04-2.20) times more likely to 
die of CVD or CHD than those with cadmium concentration of ≤ 0.61 µg/g, 
respectively, over a mean follow-up period of 15 years.  In contrast, a longitudinal study 
(9.0 year mean follow-up) undertaken by Menke et al. (2009) using a sample of 13958 
adults (≥ 20 years of age) from the NHANES population, concluded that, after 
adjustment for demographic and cardiovascular risk factors, increasing concentrations 
of urinary cadmium was not significantly associated with increased risk of CHD 
mortality in men and may be protective in women (HR = 0.45, 95% CI = 0.24-0.83).  
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The limited number of longitudinal studies makes is difficult to identify if there is a 
causal relationship between increasing urinary cadmium and CVD risk, and as cross-
sectional studies only provide evidence of associations, they are not able to identify 
these relationships (Cohen, Manion, & Morrison, 2011). Furthermore, none of the 
sample populations were focused on elderly females and only one was sampled from a 
population other than NHANES. Thus to date the studies have been limited in number 
and generalisability to broader communities, including the Australian population, which 
is why there was a need to determine whether cadmium exposure is impacting CVD in 
the Australian elderly.  
Cadmium and All-Cause Mortality 
There has also been limited research that has examined the relationship between 
increasing cadmium exposure and risk of mortality in non-occupationally exposed 
populations. In one of the longitudinal studies previously described, which sampled 
male and female American Indians (N = 3348, age  = 45-74 years), the researchers also 
examined cadmium exposure (in urine) and the risk of all-cause mortality (Tellez-Plaza, 
Guallar, Howard, et al., 2013). Using Cox proportional-hazards, the authors determined 
that, after adjustment for socio-demographic and cardiovascular risk factors, 
participants with urinary cadmium concentrations > 1.45 µg/g creatinine had an HR of 
1.58 (95% CI = 1.32-1.89) when compared with participants who had concentrations ≤ 
0.61 µg/g. In a separate longitudinal study, Tellez-Plaza et al. (2012), using a NHANES 
sample of men and women (N  = 8989, >19 years, average 4.8 year follow-up), reported 
that HR for all-cause mortality in a model adjusted for demographic and cardiovascular 
risk factors, was 1.52 (95% CI = 1.00-2.29) when comparing the 80th and 20th 
percentiles of urinary cadmium concentrations.  
Finally, Menke et al. (2009), also using an NHANES sample (N = 13958, >19 years, 
average 9.0 years follow up), concluded that there was no statistically significant 
relationship (p = 0.81) between tertiles of urinary cadmium concentrations (< 0.29 µg/g, 
0.29-0.67 µg/g and >0.67 µg/g) and all-cause mortality in female participants when 
adjusted for demographic and cardiovascular risk factors, even though an increased risk 
of all-cause mortality was identified for men in this study. These studies indicate that a 
relationship between increasing urinary cadmium concentrations and an increase in risk 
of mortality may exist. Further, all studies that were identified in the literature have 
been compared in depth and can be found in Appendix A, Table 17. 
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Rationale for Research 
Given the significant burden CVD has on the health of the Australia population and the 
relative health expenditure, it is important to identify factors associated with risk of the 
disease. Although there is limited literature currently, the research that has been 
conducted thus far suggests an association between increased urinary cadmium 
concentrations and incidence of CVD, as well as all-cause mortality. However, most of 
the studies to date have only been able to examine this relationship cross-sectionally. 
Furthermore, there has been no research conducted investigating this potential 
association in an Australian population. Even though the relationships has been 
examined in other populations have been examined, variations in diet and soil 
concentrations of cadmium in other countries, as well as lifestyle factors all effect 
overall environmental exposure, which limits the generalisability of studies conducted 
overseas to Australian populations. There was also no research identified in the 
literature that examined elderly populations only. This project provided a unique 
opportunity to access 15 years of longitudinal data collected by the BVRG, which 
included baseline urine samples and hospitalisation data, to study whether an 
association exists between cadmium exposure and CVD in elderly women from Perth, 
Western Australia.  
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Method 
Design 
Using urine samples that were collected in 1998 (baseline) by the BVRG, urinary 
cadmium concentrations were analysed, which were then compared to demographic and 
cardiovascular risk factors as well as hospitalisation morbidity and mortality 
information collected annually between 1998 and 2013. This quantitative longitudinal 
study was designed to assess the relationship between increasing urinary cadmium 
concentrations and the risk of five CVD outcomes, as well as all-cause mortality, in a 
large cohort of elderly women from Perth, Western Australia.  
Participants  
The research was based on data previously collected for the Calcium Intake Fracture 
Outcome Study (CAIFOS) by the BVRG and therefore the researcher did not recruit 
any of the participants. The CAIFOS study, originally employed a population based 
approach to recruit 1500 women over 70 years of age, from the Western Australian 
electoral roll, which included more than 99% of potential participants as voting is 
compulsory. Initially, the BVRG mailed 24,800 invitations to the potential participants, 
from which there were 431243 respondents, of which 1222 were excluded as they did 
not meet the criteria set out by the study, and 1580 responded that they were not 
interested in participating. After further exclusions and withdrawals, the final study 
population was 1460. For classification purposes, even though the subjects were on 
average, of higher socio-economic status, they were not different to the rest of the 
population in health resource utilisation (Bruce, Devine, & Prince, 2002). Furthermore, 
as the initial study was a fracture outcome study none of the recruited women were 
using active bone agents or had any illness that would likely to limit their ability to 
participate in the 5-year study.  
The participants were followed from 1998 to the conclusion on the CAIFOS in 2003 
(Prince, Devine, Dhaliwal, & Dick, 2006). Thereafter, 1136 of the women re-enrolled to 
continue in a follow up study, CAIFOS Age Related Extension Study (CARES), which 
collected information between 2003 and 2008 about the subject’s dietary habits, as well 
as other factors that influence osteoporosis risk and other chronic diseases. Finally, 746 
women who were still interested, re-enrolled again into another BVRG study, entitled 
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CAIFOS Age Related Extension Extension Study (CAREES), which ran between 2008 
and 2013.  
 
Figure 1. Timeline and overview of study. 
 
 
 Association between Cadmium and CVD  
 
11 
Analysis of Cadmium in Urine 
Baseline spot morning urine samples (not first void) were collected by the BVRG in 
1998 from 1359 participants, frozen and stored at -20 °C at Sir Charles Gairdner 
Hospital, Perth. In 2014, the researcher thawed the samples and extracted 2.5 mL 
aliquots, vortexed and prepared for metals analysis at Edith Cowan University, 
Joondalup, Western Australia. Initially, 0.4mL of urine was transferred into a metal free 
polypropylene 10mL tube with a metal free pipette tip. Added to this was 3.6mL Merck 
Nitric acid 2% Suprapur. The samples were then mixed. Prior to any sample analysis, 
seven standards were prepared over the range of 0.02 to 500 mg/L from stock standards 
(ACR) containing elements of interest, in Merck Nitric acid 2% Suprapur. Then a mixed 
10 mg/L Internal Standard containing Sc, Ge, Y, Rh, Te, were prepared in Merck Nitric 
acid 2% Suprapur. A ClinChek- control (Recipe) Level 1 and 2 were prepared as per 
instructions. They were then diluted as per samples. Simultaneously, verification 
standards ICP-MS-E (High Purity Standards) of 2, 50, 100 mg/L were prepared in 
Merck Nitric acid 2% Suprapur. The samples were then analysed on a Thermo Fisher 
iCAP Q ICP-MS using an autosampler (Thermo Scientific Inc., New York, United 
States). The new peristaltic pump tubing was used with each batch and the rinse 
solution used was Merck Nitric acid 2% Suprapur with 50 mL/L of Triton X (Merck). 
Calibration checks were run every 20 samples if check samples outside calibrations, if 
they were outside a new calibration was performed. New calibration was also run every 
60 samples. 
Furthermore, in September 2014, the researcher assisted staff at Pathwest, Nedlands, 
where samples were measured for creatinine by the Jaffe reaction using an Abbott 
Architect c16000 auto analyser (Abbott Laboratories, Illinois, USA). Finally, aliquots of 
urine were analysed in November 2014 for specific gravity, also by the researcher, 
using an Atago Master Refractometer (Atago Co., Tokyo, Japan), at the School of 
Medical Sciences, ECU. 
Demographics 
All demographic information from the CAIFOS population was collected by the BVRG 
at baseline in 1998; and included disadvantage by postcode, ever smoking, weight, 
height and subsequently body mass index (BMI).  Disadvantage was measured using 
the 1996 Socio-economic indexes for areas (SEIFA) information paper (ABS, 1998). 
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Smoking history was categorised as never smoked or ever smoked, those who had 
smoked at least one cigarette every day for three months at any period during their life 
were considered ever smokers. Weight was measured using scales (kilograms) and 
height using a stadiometer (metres).  
CVD Risk Factors 
Several measures of cardiovascular and metabolic health were collected and recorded 
by the BVRG at baseline. Pre-existing diabetes and hypertension, along with yes/no 
answers for the use of cardiovascular medications (anti-hypertensives, statins and low 
dose aspirin) were taken.  Systolic (SBP) and diastolic blood pressure (DBP) were 
measured using the right arm, after the subject had been reclined and rested for 5 
minutes, using a mercury column manometer. Three measurements were taken and used 
to calculate mean arterial pressure (MAP) ((2 x DBP) + SBP) / 3). A Hitachi 917 auto 
analyser (Roche Diagnostics, Mannheim, Germany) was used to measure total 
cholesterol, high-density lipoprotein cholesterol (HDLC) and serum triglyceride 
concentrations. Low-density lipoprotein cholesterol (LDLC) was calculated using 
Friedewald’s method (Friedewald, Levy, & Fredrickson, 1972). The Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation was used to calculate 
estimated glomerular filtration rate (eGFR) (Levey et al., 2009). Cystatin C 
measurements were performed in 2008 from stored sera and analysed according to 
international guidelines (Lim et al., 2014). 
Intimal-medial Thickness 
Mean and maximum common carotid artery intimal medial thickness (CCA IMT) are 
screening tools used as an indicator for the severity of atherosclerosis (Mukherjee & 
Yadav, 2002). CCA IMT was measured three years into the original CAIFOS study 
using the B-mode carotid ultrasound method (Lewis, Zhu, Thompson, & Prince, 2014). 
The distal portions of the far right and far left common carotid arteries were measured 
for thicknesses from three different angles, to limit asymmetrical interference. Mean 
CCA IMT was calculated by averaging the carotid thickness of the intimal-medial layer 
in the six images. Maximum CCA IMT was also calculated from these images. 
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Outcome variables 
The 16 end points that were selected as part of the study were variations of six health 
outcomes: all-cause mortality, ASVD, HF, PAD, CVA and CHD. For the last four 
health outcomes mentioned, three measures of each outcome were used: a 
hospitalisation measurement, a multiple causes of death (including the specified health 
outcome) measurement and a combined measurement of both. For example, HF, 
multiple causes of death HF and HF event will be the terms used to refer to the health 
outcomes relating to heart failure. Multiple causes of death for a health outcome are 
identified when a condition is not listed on the death certificate as the primary condition 
directly causing death, but rather an antecedent or contributing cause (AIHW, 2007). 
Analysis of ASVD included death by ASVD (ASVD death), hospitalisation by ASVD 
(ASVD hospitalisation) and ASVD (ASVD death and ASVD hospitalisation combined). 
Where death by ASVD was defined, it was determined as the primary cause of death. 
Furthermore, all-cause mortality was not grouped. 
Western Australian Hospital Morbidity Data System (HMDS) 
Hospitalisation information for all participants who enter private and public hospitals in 
Western Australia is collected, categorised and entered into the Western Australian 
Hospital Morbidity Data System (HMDS), by hospital staff and has been done so since 
the 1970’s. Information is recorded in accordance with the International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision, Australian 
Modification (ICD-10-AM) (1998-present) and previously the International Statistical 
Classification of Diseases, Injuries and Causes of Death: Clinical Modification (ICD-9-
CD) (1970-1997). Access to the hospitalisation data of the study participants for the 15-
year study period (from the beginning of CAIFOS in 1998 to the completion of the 
CAREERS cohort in 2013) was made possible by the BVRG. Participant mortality data 
were available from the Western Australian Data Linkage System, which was also 
accessed through the BVRG. 
Through the analysis of literature previously published by the BVRG on heart health 
(Ivey, Lewis, Prince, & Hodgson, 2013; Lewis, Calver, Zhu, Flicker, & Prince, 2011), 
the following ICD10-AM codes were identified and utilised as part of the study: 
coronary heart disease (I20-I25), heart failure (I50), peripheral arterial disease 
excluding haemorrhagic (I70-I74) and cerebrovascular disease excluding haemorrhagic 
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(I63-I69). Information of prevalent CVD (codes 309-459), CHD (codes 410-414), HF 
(code 428), CVA (codes 433-438), PAD (codes 440-444) and ASVD (codes 410-414, 
428, 433-438 and 440-444) at baseline recorded using the ICD-9-CD classification 
codes were also collected (Lim et al., 2014). 
Ethical issues 
This nested study was located within a larger study being conducted by Professor 
Richard Prince, Associate Professor Devine, Dr Anna Callan, Dr Joshua Lewis and Dr 
Andrea Hinwood, which is examining the possible benefits or health implications 
associated with heavy metal exposure in elderly women. The metals-in-urine and health 
group currently has ethical clearance from UWA for CAIFOS and BVRG data, and the 
Department of Health’s Human Research Ethics Committee for access the WA HMDS 
data until 28 July 2017. Further, the project also has ECU ethics clearance (Project 
number 11387) for all data until 28 July 2017. As the proposed study forms part of this 
larger investigation an ethics declaration was prepared prior to commencement of data 
analysis (Project number 12120). The researcher only had access to de-identified data, 
which minimised the risk of participant confidentiality breaches and potential researcher 
bias. 
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Statistical Analysis 
Descriptive Analysis 
All statistical analyses were performed in IBM SPSS Statistics for Macintosh, Version 
22.0. However, prior to any analysis of urinary cadmium and potential health outcomes, 
the variables were tested for violations of normality using stem-and-leaf plots, 
histograms, scatterplots and Q-Q plots. The tests indicated that the urinary cadmium 
variables were not normally distributed. To improve the distribution of the data the 
variable was transformed using natural log, as it is a preferred method for positively 
skewed data (Tabachnick & Fidell, 2014). Samples of urine that had concentrations 
below the level of detection (LOD) (<0.05 µg/L) were assigned a value half of the LOD 
(Liu, Lu, Kolpin, & Meeker, 1997). 
To assess the relationship between urinary cadmium and the dependent variables 
normality of all variables were completed using Kolmogorov-Smirov (K-S) and 
Shapiro-Wilk (S-W) tests. Of the continuous variables, only low-density lipoprotein 
cholesterol (p = 0.067) was normally distributed, however, the S-W p-value for LDLC 
was less than 0.05. All other variables had a p-value of <0.001 for both K-S and S-W 
tests and therefore the assumption of normality did not hold. However, due to the large 
sample size (N = 1460), it is not unusual for the data set to be not-normally distributed 
and testing therefore proceeded. 
Tertiles of increasing urinary concentrations of cadmium were developed to stratify the 
population and analyse if there was a difference in odds of a health outcome between 
the three groups. Further, to assess the relationship between the demographic and 
population descriptors, and the tertiles of cadmium, Kruskal-Wallis and Chi-square 
independence tests were used (Field, 2009). Chi-square independence tests were also 
performed for the outcome variables and tertiles of urinary cadmium. Separately, a 
Mann-Whitney U test was performed comparing urinary cadmium concentrations in 
never and ever smokers. Effect size was calculated by first converting the z score into a 
residual value (r) using the method described by Clark-Carter (2009), and then the score 
was evaluated using recommendations by Cohen (1988). 
As most of the descriptors were not normally distributed Spearman’s correlation tests 
were undertaken (Field, 2009). These tests included all continuous demographic and 
health related variables as well as the three measures of urinary cadmium; observed, 
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creatinine corrected and specific gravity. Tests were two-tailed, with an α < 0.05. 
Measures of effect size were made according to Cohen (1988). 
Analysis of Binary Outcomes  
As the analysis contained both continuous and categorical predictor variables, and the 
outcome variable was also categorical, a logistic regression was chosen as the 
appropriate test to answer the research question (Pallant, 2013). In the initial model, the 
log-transformed observed cadmium variable, as well as the potential covariates (age, 
BMI, disadvantage, smoking status, presence of prevalent CVD, ASVD, CHD, CVA, 
PAD or HF (if applicable), diabetes, hypertension, anti-hypertensive medication use, 
systolic blood pressure, diastolic blood pressure, mean arterial pressure, total 
cholesterol, HDLC, LDLC, triglycerides, statin medication use, aspirin use, eGFR, 
Cystatin C, mean IMT and maximum IMT) were entered into a logistic regression, for 
which the explanatory variable was the end point. None of the models reported a 
residual chi-square with a significance of greater than 0.05, and as such they were all 
followed through (Field, 2009). Collinearity was also assessed for the final all-cause 
mortality model. According to Menard (2002) as tolerance was greater than 0.10 for 
each of the variables, the risk of collinearity is low and the models were completed.  
The model was then run and the confounder with the smallest β value was removed. 
This method was repeated until only the significant predictors (p < 0.05), as well as log-
transformed observed cadmium variable, remained. The dataset was then stratified by 
smoking history and the analysis repeated. Afterwards, the cadmium variable was 
replaced by tertiles of observed cadmium and the process of identifying only the 
variables that were significant was repeated, including the stratification by smoking 
history comparisons. Furthermore, the process was undertaken for each of the 16 
dependent binary variables (all-cause mortality, atherosclerotic vascular disease death, 
atherosclerotic vascular disease event, atherosclerotic vascular disease hospitalisation, 
heart failure, multiple causes of death including heart failure, heart failure event, 
peripheral arterial disease, multiple causes of death including peripheral arterial disease, 
peripheral arterial disease event, cerebrovascular accident, multiple causes of death 
including cerebrovascular accident, cerebrovascular accident event, coronary heart 
disease, multiple causes of death including coronary heart disease and coronary heart 
disease event). Final models are presented with confounding variables that were 
significant (p < 0.05) included. 
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Survival Analysis 
The most appropriate test for measuring the effect of urinary cadmium and the 
confounders on the probability of survival of the sample population was the Cox 
proportional-hazards model (Bradburn, Clark, Love, & Altman, 2003; Cox, 1972). The 
model was selected as it is semi-parametric test, which is able to deal with multiple 
variables that may not be normally distributed and it does not assume the shape of the 
hazard function like a parametric survival model (Flynn, 2012). As urinary cadmium is 
the explanatory variable, only health outcomes for which urinary cadmium was a 
significant predictor in the logistic regression models were included in the subsequent 
Cox proportional-hazards analyses.  
However, prior to any Cox proportional-hazards analyses the outcome variables were 
tested to see if there was a statistically significant difference in the survival frequency of 
the three groups of urinary cadmium (tertiles of increasing urinary cadmium 
concentrations) (Flynn, 2012; Kaplan & Meier, 1958). To achieve this, Kaplan-Meier 
tests, as well as significance tests, were undertaken (Flynn, 2012). Kaplan-Meier plots, 
being univariate tests, are limited in their external validity because they do not consider 
the influence of potential confounders (Clark, Bradburn, Love, & Altman, 2003a), 
nevertheless they provided an indication of statistical differences between the tertiles. 
Predictive ability of the proportional hazards, including calibration and discrimination, 
have not been conducted as they are beyond the scope of the study (Clark, Bradburn, 
Love, & Altman, 2003b).  
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Results 
Demographic & Health Characteristics 
Baseline Demographics 
Overall, the mean (SD) age for the sample of elderly women was 75.2 (2.7) years. The 
participants of this study were less disadvantaged than the general population, with 
almost one third (30.6%) being in the SEIFA’s ‘top 10% least disadvantaged’. Overall, 
the cohort was overweight, 65.8% of the participants recording a BMI at baseline that 
classified them as either overweight or obese (BMI > 25.0 kg/m2) and the mean (SD) 
BMI of the cohort was 27.2 (4.8) kg/m2 (Table 1). More than one third (37.1%) of 
participants reported a history of smoking at baseline. One in five (23.2%) participants 
entered the study with prevalent CVD and one in eight reported prevalent ASVD 
(12.2%). Fewer participants reported prevalent CHD (8.7%), CVA (3.3%), PAD (1.1%) 
or HF (0.3%) at baseline (Table 1).  
Kruskal-Wallis and Chi-square independence tests were used to assess the relationship 
between the independent variables and the low (≤ 0.155 µg/L), medium (> 0.155 – 
0.255 µg/L) and high tertiles (> 0.255µg/L) of urinary cadmium concentrations (Table 
1). The test indicated that there was a statistically significant relationship between 
smoking history and tertiles of urinary cadmium (χ2 (2, N = 1352) = 16.853, p < 0.001) 
(Table 1). The proportion of participants who have ever smoked increased across the 
low, medium and high concentration tertiles, with 43.8% of individuals in the highest 
cadmium concentration tertile reporting ever smoking compared with 30.7% in the 
lowest tertile of cadmium exposure (Table 1). However, as φ = 0.11, the association is 
considered small. No other statistically significant relationships were identified in the 
baseline demographics (Table 1).  
Health Outcomes  
Chi-squared tests for independence revealed statistically significant differences between 
the tertiles of urinary cadmium were identified for four of the health outcomes, which 
were: all-cause mortality, death by ASVD, multiple causes of death HF and HF event 
(Table 2). For all-cause mortality, only 35.0% of participants died in the lowest urinary 
cadmium tertile (≤ 0.115 µg/L) died during the follow-up period, compared with 44.2% 
of those with the highest urinary cadmium group (> 0.255 µg/L). The differences in the 
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number of participant numbers in each of the other three health outcomes also followed 
a similar trend (Table 2). 
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Urinary Cadmium 
A total of 1359 baseline spot morning urine samples were analysed for cadmium 
concentration. The median (IQR) concentration of cadmium in urine was 0.180 (0.09-
0.32) µg/L (Table 3). In total, 182 (13.5%) samples were below the analytical limit of 
detection (0.05 µg/L) for cadmium. Over half the participants (54.5%) had urinary 
creatinine concentrations of less than or equal to 0.2 g/L, indicating that urine samples 
were dilute and below the usual threshold that is acceptable for creatinine adjustment of 
urinary analytes (WHO, 1996). Specific gravity measurements were also undertaken 
and the median value was 1.005 g/mL, range (1.001-1.040 g/mL) (Table 3), which 
indicated that the urine samples were dilute. As the urine samples analysed in this study 
were spot samples (collected at a morning appointment) and not first morning void 
samples and were very dilute, it was decided that statistical analysis would be 
undertaken using only the observed (unadjusted) urinary cadmium concentrations. Most 
concentrations of urinary cadmium were low, however, six participants (0.4%) had 
urinary cadmium concentrations that exceeded 10µg/L (Table 3). Observed urinary 
cadmium concentrations were not normally distributed and were therefore, natural log 
transformed and the transformed variable was used in subsequent statistical models.  
Table 3. Median (IQR) urinary cadmium concentrations in 1359 elderly women. 
Measurements of cadmium Median IQR Min. Max. 
Cadmium Observed (µg/L) 0.180 (0.09-0.32) 0.008 48.7 
Cadmium Adjusted (µg/g creatinine) 0.914 (0.49-1.52) 0.025 229 
Cadmium SG adjusted (µg/L) 0.230 (0.13-0.41) 0.180 63.8 
Urine creatinine at baseline (g/L) 0.178 (0.11-0.32) 0.050 2.35 
Specific gravity (g/mL) 1.005 (1.003-1.008) 1.001 1.040 
IQR = interquartile range; SG = specific gravity  
 
Descriptive Analysis 
Tertiles Analysis  
As previously reported, observed cadmium was stratified into tertiles of increasing 
urinary cadmium concentrations. Kruskal-Wallis and Chi-squared tests were undertaken 
to assess any relationships between the tertiles and the indicators of heart and kidney 
health (reported in Table 4). Only 6% of participants reported having diabetes at 
baseline whereas more than half the sample reported prevalent hypertension (58.3%). 
Of those who reported hypertension, 3 in 4 (74.6%) also reported anti-hypertensive 
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medication use. Although it appears that there is a difference in the number of 
participants who reported hypertension between the tertiles of urinary cadmium, a Chi-
squared test revealed no significant difference (p = 0.068). However, the relationship 
between anti-hypertensive medication and increasing urinary cadmium tertiles was 
statistically significant χ2 (2, N = 1359) = 7.551, p = 0.023, though the association was 
small (φ = 0.075), with 39.4% of participants in lowest tertile using antihypertensive 
medication compared with 48.1% in the highest tertile of cadmium. The average total 
cholesterol, a known risk factor of CVD, was above national risk reduction 
recommendations (< 4.0 mmol/L) (National Vascular Disease Prevention Alliance, 
2012). An increase in mean (SD) total cholesterol was seen across the tertiles, while 
close to the critical value (p ≤ 0.05) the difference was not statistically significant (p = 
0.067) (Table 4).  
Kidney health markers are also measured as part of the original study and are reported 
in the table below (Table 4). Thirty two per cent of participants had eGFR values below 
60mL/min/1.73 m2, indicative of impaired kidney function (National Vascular Disease 
Prevention Alliance, 2012). A Kruskal-Wallis H test indicated that there was a 
significant difference in eGFR between the three urinary cadmium tertiles (lowest 
tertile, Mean Rank = 655.68; medium tertile, Mean Rank = 585.69; highest tertile, Mean 
Rank = 600.53), χ2 = 8.877, df = 2, p = 0.012. Similarly, when a Kruskal-Wallis H test 
was conducted to assess if there was significant difference in mean Cystatin C between 
the three urinary cadmium tertiles, a p-value of <0.001 was reported with χ2 = 16.357 
and two degrees of freedom (lowest tertile, n = 358, Mean Rank = 483.93; medium 
tertile, n = 350, Mean Rank = 568.19; highest tertile, n = 367, Mean Rank = 561.95). 
Participants in the lowest tertile had a much lower reported mean (SD) Cystatin C 
concentration than those in the highest urinary tertile of cadmium (1.04 (0.20) mg/L 
compared to 1.09 (0.23 mg/L). Although the pathophysiology is not yet well 
understood, current literature indicates that there is a relationship between increasing 
Cystatin C concentrations and increased risk of CVD (Angelidis et al., 2013).  
The population mean (SD) for the mean intima-media thickness (IMT), a measure of 
plaque in the arteries, was 0.78 (0.1) mm and the mean (SD) of the maximum IMT was 
measured as 0.92 (0.1) mm. These figures are below measurements that would indicate 
an increased risk of CVD (greater than 1mm) (Prati et al., 2008; Roman et al., 2012). 
No significant difference in either mean, or maximum IMT between the tertiles of 
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urinary cadmium was identified (Table 4). Age, BMI, social disadvantage and incidence 
of self-reported diabetes did not vary between the tertiles (Table 4). 
History of Smoking 
A Mann-Whitney U test that observed urinary cadmium concentrations were 
significantly higher for ever smokers (Mean Rank = 731.55, n = 501) than those who 
had never smoked (Mean Rank = 644.09, n = 851), U = 185597, z = -3.981, p <0.001, 
two tailed. The relationship can be described as weak (r = -0.11). The median (IQR) 
observed urinary cadmium concentrations for never smokers were 0.17 (0.08-0.29) 
µg/L, compared with 0.20 (0.11-0.37) µg/L for ever smokers.  
Correlations  
When assessed as a continuous variable, increasing urine cadmium was significantly 
associated with higher Cystatin C concentrations (r = 0.092, p= 0.002) (Table 5).  
Similarly, BMI and observed urinary cadmium concentrations were also significantly 
correlated (r = 0.062, p = 0.022), although the association was weak. No association 
was seen between observed cadmium concentrations and age, systolic blood pressure, 
diastolic blood pressure, mean arterial pressure, total cholesterol, HDLC, LDLC, 
triglycerides, eGFR, mean IMT or maximum IMT (Table 5).  
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All-cause Mortality 
Logistic regression analysis was used to evaluate the relationship between observed 
urinary cadmium concentrations and the probability of study participants dying during 
the 15-year (or 174 month) follow-up period. The number of participants who died 
during that time was 592 (39.5%).  The final model for the total population was 
adjusted for six significant independent variables, with OR’s for these cofounders 
ranging from 1.101 to 2.727 (Table 6). In the total population analyses no statistically 
significant relationship was identified between the log-transformed urinary cadmium 
variable and all-cause mortality. However, when the sample was stratified by smoking 
history, ever smokers who had increased urinary cadmium concentrations were at 
significantly greater odds of dying (OR = 1.423, 95% CI = 1.153-1.756). Several 
confounding variables that were significant in the total population and for never 
smokers were not significant predictors for the odds of death occurring in ever smokers 
(Table 6). 
Table 6 Logistic regression for all-cause mortality within the total population (N = 1359), 
and the never smoked (n = 851) and ever smoked populations (n = 501), for log 
transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% C.I. for OR 
  
Lower Upper 
Total Population Urinary cadmium .108 .065 1.114 .993 1.251 
Age .096 <.001 1.101 1.050 1.154 
Ever smoked .373 .006 1.453 1.114 1.894 
Hypertension .379 .005 1.461 1.121 1.905 
 
Low dose aspirin .392 .014 1.480 1.082 2.026 
 
Cystatin C 1.003 .001 2.727 1.470 5.057 
 
Prevalent CVD .453 .004 1.572 1.158 2.135 
 
Constant -9.070 <.001 <.001         
Never Smoked Urinary cadmium -.020 .787 .981 .850 1.131 
 
Age .139 <.001 1.149 1.080 1.222 
 
Hypertension .590 .001 1.803 1.278 2.544 
 
Low dose aspirin .471 .020 1.602 1.079 2.380 
 
Cystatin C 1.185 .006 3.271 1.413 7.571 
 
Prevalent CVD .118 .558 1.125 .759 1.667 
 
Constant -12.769 <.001 <.001         
Ever Smoked Urinary cadmium .353 .001 1.423 1.153 1.756 
 
Age .049 .219 1.050 .971 1.136 
 
Hypertension .082 .708 1.086 .706 1.671 
 
Low dose aspirin .208 .446 1.231 .721 2.102 
 
Cystatin C .774 .112 2.169 .836 5.627 
 
Prevalent CVD 1.042 <.001 2.834 1.689 4.755 
 Constant -4.453 .132 .012   
Nagelkerke R2 = 10.8%, 12.1% and 13.1%; Correct case classification = 63.9%, 66.3%% and 62.6%. 
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The analysis was repeated with cadmium concentration by tertile replacing the 
continuous variable. This analysis identified that there was no significant difference 
between the tertiles of increasing urinary cadmium in odds of dying in the total 
population (Table 7). However, when the dichotomous variable for smoking history was 
used to stratify the model, ever smokers with the highest urinary cadmium 
concentrations (> 0.255 µg/L) had significantly higher odds of dying than those with the 
lowest levels of urinary cadmium (≤ 0.155 µg/L) (OR = 2.015, 95% CI = 1.190-3.411). 
In the total population, the odds of mortality were increased by ageing, a history of 
smoking, self-reported hypertension, aspirin use, lower Cystatin C concentrations and a 
history of CVD. Although most of the same confounding variables were significant for 
the never smoked population compared to the total population, the only significant 
confounding risk factor for ever smokers was the presence of prevalent CVD.  
Table 7. Logistic regression for all-cause mortality within the total population (N = 1359), 
and the never smoked (n = 851) and ever smoked populations (n = 501), for tertiles of 
observed urinary cadmium. 
    
B Sig. 
Odds 
Ratio 
95% C.I. for OR 
  
Lower Upper 
Total Population Low urinary Cd   .224       
Medium urinary Cd .158 .334 1.171 .850 1.615 
High urinary Cd .278 .084 1.321 .963 1.812 
Age .096 <.001 1.101 1.050 1.155 
 
Ever smoked .373 .006 1.453 1.114 1.894 
 
Hypertension .374 .006 1.453 1.114 1.895 
 
Low dose aspirin .400 .013 1.491 1.090 2.041 
 
Cystatin C <.001 .002 2.719 1.464 5.048 
 
Prevalent CVD .454 .004 1.575 1.160 2.139 
 
Constant -9.411 <.001 <.001         
Never Smoked Low urinary Cd  .574    
 
Medium urinary Cd .178 .383 1.195 .801 1.784 
 
High urinary Cd -.020 .925 .980 .651 1.478 
 
Age .138 <.001 1.148 1.079 1.221 
 
Hypertension .601 .001 1.823 1.290 2.577 
 
Low dose aspirin .475 .019 1.608 1.082 2.390 
 
Cystatin C 1.156 .007 3.178 1.372 7.363 
 
Prevalent CVD .114 .570 1.121 .756 1.662 
 
Constant -12.687 <.001 <.001         
Ever Smoked Low urinary Cd  .017    
 
Medium urinary Cd .167 .554 1.182 .679 2.058 
 
High urinary Cd .701 .009 2.015 1.190 3.411 
 
Age .043 .280 1.044 .966 1.128 
 
Hypertension .046 .833 1.047 .681 1.611 
 
Low dose aspirin .255 .347 1.291 .758 2.198 
 
Cystatin C .795 .103 2.214 .853 5.750 
 
Prevalent CVD 1.029 <.001 2.799 1.669 4.693 
 Constant -4.895 .097 .007     
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Nagelkerke R2 = 10.8%, 12.3% and 12.1%; Correct case classification = 63.7%, 66.9%% and 62.9%. 
 
Death by Atherosclerotic Vascular Disease  
Logistic regression analysis was used to analyse the relationship between increasing 
urinary cadmium concentrations and the odds of death from atherosclerotic vascular 
disease (ASVD). A total of 318 participants died of ASVD during the 14.5-year follow-
up period. The model indicated that in the total population, urinary cadmium 
concentration was associated with an increased risk of death from AVSD (OR = 1.156, 
95% CI = 1.015-1.315), even after adjustment for confounders (Table 8). However, this 
finding was no longer significant when the logistic regression was stratified smoking 
history. When the models were run with urinary cadmium by tertile included instead of 
the continuous variable, the increase in odds of death from ASVD between those in the 
lowest and highest tertile was not significant in any of the analyses (Appendix B, Table 
18). 
Table 8. Logistic regression for atherosclerotic vascular disease death within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .145 .029 1.156 1.015 1.315 
 Age .117 <.001 1.124 1.066 1.186 
 BMI .045 .005 1.046 1.014 1.078 
 Hypertension .413 .009 1.511 1.106 2.064 
 
Low dose aspirin .515 .003 1.674 1.196 2.343 
 
eGFR -.015 .009 .985 .975 .996 
 
Prevalent ASVD .888 <.001 2.431 1.643 3.596 
 
Constant -10.716 <.001 <.001         
Never Smoked Urinary cadmium .110 .189 1.116 .947 1.316 
 
Age .195 <.001 1.215 1.130 1.307 
 
BMI .042 .047 1.043 1.001 1.087 
 
Hypertension .665 .002 1.945 1.277 2.963 
 
Low dose aspirin .638 .004 1.892 1.230 2.912 
 
eGFR -.009 .214 .991 .976 1.005 
 
Prevalent ASVD .552 .042 1.737 1.020 2.957 
 
Constant -17.227 <.001 <.001 
  
Ever Smoked Urinary cadmium .107 .343 1.113 .892 1.389 
 
Age .009 .843 1.009 .926 1.099 
 
BMI .041 .090 1.042 .994 1.093 
 
Hypertension .087 .727 1.090 .671 1.772 
 
Low dose aspirin .406 .160 1.500 .852 2.642 
 
eGFR -.018 .043 .982 .965 .999 
 
Prevalent ASVD 1.322 <.001 3.750 2.024 6.947 
 Constant -1.955 .581 .142     
Nagelkerke R2 = 14.0%, 16.3% and 14.7%; Correct case classification = 79.5%, 82.0% and 77.4%. 
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Multiple Cause of Death, Heart Failure 
Logistic regression was undertaken to assess the relationship between known CVD risk 
factors, observed urinary cadmium and multiple cause of death heart failure (n = 88). Of 
the 17 covariates that were entered into the initial model, only two remained in the final 
model (Table 9). Observed urinary cadmium was significantly associated with odds of 
multiple cause of death HF in both the overall model (OR = 1.414, 95% CI = 1.141-
1.751) and within the never smoked population (OR = 1.304, 95 CI = 1.026-1.657). The 
strongest confounding risk factor of multiple cause of death HF in the total population 
was prevalent HF, such that those who self-reported prevalent heart disease at baseline 
were 13 times more likely to have multiple cause of death HF (13.706, 1.665-112.835). 
However, the relationship with prevalent HF was removed when the population was 
stratified by smoking history, which may reflect the small number of participants who 
died from multiple cause death heart failure.  
Table 9. Logistic regression for multiple cause death by heart failure within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .346 .002 1.414 1.141 1.751 
Cystatin C 1.504 .002 4.499 1.774 11.409 
Prevalent HF 2.618 .015 13.706 1.665 112.835 
Constant -3.847 <.001 .021          
Never Smoked Urinary cadmium .266 .030 1.304 1.026 1.657 
 Age .159 .003 1.172 1.055 1.303 
 
BMI .040 .198 1.041 .979 1.105 
Constant -15.490 <.001 <.001          
Ever Smoked Urinary cadmium .286 .117 1.332 .931 1.905 
 Age .127 .079 1.135 .986 1.308 
 BMI .107 .002 1.113 1.041 1.190 
  Constant -14.971 .010 <.001     
Nagelkerke R2 = 5.7%, 5.4% and 7.4%; Correct case classification = 93.7%, 94.4% and 94.4%. 
 
When urinary cadmium concentration was expressed in tertiles, the logistic analysis 
revealed that in the total population, participants with urinary cadmium concentrations 
>0.255 µg/L had a significantly higher odds of multiple cause of death HF (OR = 2.769, 
95% CI = 1.439-5.327) compared to those in the lowest tertile (≤0.115µg/L) (Table 10). 
There was also a statistically significant increase in odds of multiple cause of death HF 
between the highest and lowest urinary cadmium concentrations in the never smoking 
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population (OR = 2.422, 95% CI = 1.149-5.105). Although the OR was greater than one 
for ever smokers in the highest urinary cadmium tertile (> 0.255 µg/L), the relationship 
was not statistically significant (p = 0.058) (Table 10). Cystatin C was a strong predictor 
of multiple cause of death HF risk in the total population (OR = 4.751, 95% CI = 1.899-
11.886), and even after adjustment for it in the models, increased urinary cadmium was 
associated with increased odds of multiple cause death HF occurring during the follow 
up period. 
Table 10 Logistic regression for multiple cause death by heart failure within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for tertiles of observed urinary cadmium. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd  .003    
Medium urinary Cd .282 .451 1.326 .637 2.764 
High urinary Cd 1.018 .002 2.769 1.439 5.327 
Cystatin C 1.558 .001 4.751 1.899 11.886 
 
Constant -4.953 <.001 .007         
Never Smoked Low urinary Cd  .056    
 
Medium urinary Cd .392 .337 1.480 .665 3.292 
High urinary Cd .884 .020 2.422 1.149 5.105 
 
Age .161 .003 1.174 1.057 1.304 
BMI .038 .224 1.038 .977 1.104 
 Constant -16.462 <.001 <.001          
Ever Smoked Low urinary Cd  .027    
 
Medium urinary Cd -.197 .761 .821 .230 2.932 
 
High urinary Cd 1.000 .058 2.718 .968 7.630 
 
Age .128 .079 1.137 .985 1.312 
 
BMI .110 .001 1.116 1.044 1.194 
 Constant -16.066 .006 <.001   
Nagelkerke R2 = 5.7%, 5.8% and 10.3%; Correct case classification = 93.7%, 94.2% and 94.4%. 
 
Heart Failure Event 
Heart failure events were recorded during the follow up period (174 months) in 11.7% 
of the study participants (n = 176). A logistic regression was performed to identify 
whether urinary cadmium concentration increased the odds of experiencing a HF event, 
after adjusting for demographic and heart health risk factors (Table 11). Observed 
urinary cadmium was found to be associated with increased odds of HF event in the 
total population also (OR = 1.181, 95% CI = 1.002-1.391). The odds associated with 
increased urinary cadmium were greater than one in the ever smoked population (OR = 
1.627, 95% CI = 1.089-2.341). Increased urinary cadmium concentrations were not 
associated with increased odds of heart failure event in those who had never smoked 
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(Table 11). Hypertension, increasing BMI and increasing Cystatin C concentrations 
were all predictors of HF in the total population, with Cystatin C being the strongest 
confounding factor (OR = 4.582, 95% CI = 2.281 -10.324). Even after adjustment for 
known risk factors, urinary cadmium remained significant in the models for the total 
population and ever smokers.   
Table 11. Logistic regression for heart failure event within the total population (N = 1359), 
and the never smoked (n = 851) and ever smoked populations (n = 501), for log 
transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .166 .047 1.181 1.002 1.391 
BMI .046 .015 1.047 1.009 1.087 
Hypertension .705 .001 2.023 1.326 3.087 
Cystatin C 1.579 <.001 4.852 2.281 10.324 
 
Constant -5.164 <.001 .006         
Never Smoked Urinary cadmium .014 .904 1.014 .805 1.279 
 
Diabetes 1.244 .011 3.471 1.329 9.062 
 
Hypertension .958 .002 2.605 1.436 4.725 
 
HDLC .020 .031 1.020 1.002 1.039 
 
Cystatin C 1.656 .008 5.236 1.530 17.914 
 
Constant -5.475 <.001 .004         
Ever Smoked Urinary cadmium .487 .018 1.627 1.089 2.431 
 
Diabetes 1.117 .053 3.056 .983 9.495 
 
Hypertension .984 .043 2.674 1.033 6.924 
 
HDLC -.010 .519 .990 .961 1.020 
 
Cystatin C 2.854 <.001 17.355 3.872 77.785 
 Constant -4.943 <.001 .007   
Nagelkerke R2 = 9.3%, 10.7% and 21.2%; Correct case classification = 87.4%, 87.0% and 88.9% 
 
 
Logistic regression analysis was repeated with the increasing urinary cadmium tertiles. 
Although cadmium concentrations were a significant predictor of HF events occurring 
in the total population for the model containing a continuous cadmium variable, it was 
not the case in the observed cadmium tertile modelling (Table 12). However, ever 
smokers with cadmium concentrations greater than 0.255 µg/L were almost five times 
more likely to have an HF event (OR = 4.823, 95% CI = 1.295-17.966) than those with 
the lowest urinary cadmium concentrations (≤0.115µg/L). When the analysis was 
restricted to those who had never smoked, increased urinary cadmium was not 
associated with significantly increased odds of heart failure events occurring. Similar to 
the continuous urinary cadmium modelling, hypertension, increasing BMI and 
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increasing Cystatin C were all predictors of HF event risk in the total population (Table 
12). 
Table 12. Logistic regression for HF event within the total population (N = 1359), and the 
never smoked (n = 851) and ever smoked populations (n = 501), for log transformed 
urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .178       
Medium urinary Cd .284 .256 1.329 .814 2.170 
High urinary Cd .445 .063 1.560 .976 2.495 
BMI .047 .013 1.048 1.010 1.088 
 
Hypertension .696 .001 2.005 1.313 3.061 
 
Cystatin C 1.562 <.001 4.771 2.239 10.165 
 
Constant -5.702 <.001 .003         
Never Smoked Low urinary Cd  .647    
 
Medium urinary Cd .289 .387 1.335 .694 2.571 
 
High urinary Cd .058 .867 1.059 .540 2.080 
 
Diabetes 1.267 .010 3.551 1.352 9.331 
 
Hypertension .971 .001 2.639 1.450 4.804 
 
HDLC .019 .039 1.019 1.001 1.038 
 
Cystatin C 1.598 .012 4.943 1.429 17.093 
 
Constant -5.527 <.001 .004         
Ever Smoked Low urinary Cd  .045    
 
Medium urinary Cd .909 .214 2.481 .591 10.417 
 
High urinary Cd 1.573 .019 4.823 1.295 17.966 
 
Diabetes 1.187 .043 3.276 1.039 10.331 
 
Hypertension .958 .048 2.606 1.007 6.744 
 
HDLC -.010 .514 .990 .961 1.020 
 
Cystatin C 2.901 <.001 18.196 4.061 81.539 
 Constant -6.746 <.001 .001     
Nagelkerke R2 = 9.2%, 11.0% and 22.1%; Correct case classification = 87.5%, 86.8% and 89.7% 
 
 
Peripheral Arterial Disease 
The number of participants who developed peripheral artery disease by end of study 
was 72 (4.8%). To determine whether urinary cadmium was associated with increased 
odds of PAD, analysis by logistic regression was undertaken with adjustment for 
potential confounders. Urinary cadmium was not associated with increased odds of 
PAD in the total population or the stratified analyses. Although there was an increased 
odds of PAD for ever smokers in the highest urinary cadmium tertile (OR = 2.512, 95% 
CI = 0.079-6.442), it was not significant in the model (Table 13). In the total population, 
ever smoking, hypertension and increasing Cystatin C concentrations were associated 
with the probability of PAD occurring and these covariates were used to adjust the 
model. No significant relationship was identified between the continuous urinary 
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cadmium variable and PAD in any of the populations (for table see Appendix B, Table 
24). 
Table 13. Logistic regression for peripheral arterial disease within the total population (N 
= 1359), and the never smoked (n = 851) and ever smoked populations (n = 501), for 
tertiles of observed urinary cadmium. 
    
B Sig. 
Odds 
Ratio 
95% OR 
    Lower Upper 
Total 
Population 
Low urinary Cd   .355    
Medium urinary Cd .439 .267 1.551 .715 3.368 
High urinary Cd .538 .157 1.712 .813 3.606 
Ever Smoked .764 .009 2.147 1.215 3.793 
Hypertension .651 .045 1.917 1.015 3.624 
Cystatin C 1.411 .007 4.102 1.473 11.422 
Constant -5.673 <.001 .003   
       
Never Smoked Low urinary Cd 
 .407    
Medium urinary Cd .570 .220 1.767 .712 4.388 
High urinary Cd .090 .859 1.094 .407 2.942 
Diabetes 1.758 <.001 5.799 2.290 14.683 
Hypertension 1.031 .028 2.803 1.115 7.048 
Constant -4.515 <.001 .011   
       
Ever Smoked Low urinary Cd 
 .047    
 
Medium urinary Cd .012 .983 1.012 .331 3.093 
 
High urinary Cd .921 .055 2.512 .979 6.442 
 
Diabetes -.361 .634 .697 .158 3.083 
 
Hypertension .370 .337 1.448 .681 3.080 
 
Constant -3.317 <.001 .036     
Nagelkerke R2 = 6.8%, 8.2% and 3.8%; Correct case classification = 95.1%, 96.6% and 93.4% 
 
Peripheral Arterial Disease Event 
Peripheral arterial disease event includes participants who have been hospitalised due to 
PAD and also participants whose death includes PAD (multiple causes of death PAD). 
During the follow-up period there were 89 (5.9%) participants who had a PAD event. 
No significant relationships between the continuous urinary cadmium variable and the 
odds of PAD event were identified in the whole population or when the analysis was 
stratified by smoking (Appendix B, Table 25). When the analysis was performed using 
the cadmium tertiles in place of the continuous urinary cadmium variable, there was no 
relationship between low, medium and high concentrations of urinary cadmium and 
PAD event in the total population. However, when the population was stratified by 
smoking history, cadmium exposure was a predictor of PAD event in both ever and 
never smokers (Table 14). In never smokers, participants with urinary cadmium 
concentrations in the medium tertile (> 0.115 – 0.255 µg/L) were twice as likely to have 
 Association between Cadmium and CVD  
 
35 
reported a PAD event than those with the lowest concentrations during the follow-up 
period (< 0.115 µg/L) (OR = 2.260, 95% CI = 1.011-5.053). In those who had ever 
smoked, it was the participants in the highest urinary cadmium tertile (> 0.255 µg/L) 
who were at increased odds of PAD event, when compared to those in the lowest 
urinary cadmium tertile (OR = 2.639, 95% CI = 1.101-6.327) (Table 14). Similar to 
PAD, ever smoking, hypertension and increasing Cystatin C concentrations were all 
predictors of PAD events occurring in the total population. Diabetes and hypertension 
were significant risk factors in never smokers, but no covariates were significant in ever 
smokers. 
Table 14. Logistic regression for peripheral arterial disease event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for tertiles of observed urinary cadmium. 
          95% OR 
    B Sig. Odds Ratio Lower Upper 
Total 
Population 
Low urinary Cd  .206    Medium urinary Cd .542 .132 1.720 .849 3.484 
High urinary Cd .592 .090 1.808 .912 3.586 
Ever Smoked .659 .012 1.933 1.155 3.235 
Hypertension .690 .020 1.993 1.117 3.556 
Cystatin C 1.297 .008 3.657 1.405 9.523 
Constant -5.348 <.001 .005          
Never Smoked Low urinary Cd  .063    Medium urinary Cd .816 .047 2.260 1.011 5.053 
High urinary Cd -.008 .986 .992 .394 2.495 
Diabetes 1.826 <.001 6.206 2.668 14.435 
Hypertension 1.232 .004 3.429 1.471 7.993 
Constant -4.480 <.001 .011          
Ever Smoked Low urinary Cd  .018    
Medium urinary Cd -.008 .988 .992 .350 2.816 
High urinary Cd .971 .030 2.639 1.101 6.327 
Diabetes -.563 .456 .569 .130 2.502 
Hypertension .382 .284 1.466 .728 2.951 
Constant -3.156 <.001 .043     
Nagelkerke R2 = 6.6%, 10.8% and 4.6%; Correct case classification = 94.0%, 95.5% and 92.2% 
 
 
Other CVD outcomes 
Tables providing the significant results for exposure to cadmium (when expressed as a 
continuous variable or in tertiles) and CVD outcomes are reported in this section. 
Analysis was also undertaken with the following outcomes: atherosclerotic vascular 
disease hospitalisation, atherosclerotic vascular disease event, heart failure, multiple 
cause of death peripheral arterial disease, coronary heart disease, coronary heart disease 
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event, multiple cause of death coronary heart disease, cerebrovascular accident, 
cerebrovascular accident event and multiple cause of death cerebrovascular accident, 
however, in each case increased urinary cadmium concentrations were not associated 
with significantly increased odds of the outcome occurring. These results are presented 
in Tables 18-40 (Appendix B). Prevalent hypertension was identified as a significant 
covariate in 12 of the 16 outcome variables. Age and self-reported aspirin use were 
significant predictors for nine outcome variables.  
Survival Analysis 
All-cause Mortality 
In order to determine the influence of urinary cadmium on the survival of the 
participants and their time to death during the 15-year follow up, survival analysis with 
Cox regression was used. A Kaplan-Meier plot was used first as it allowed the 
researcher to identify whether there was a relationship between our independent 
variable, urinary cadmium concentrations, and the main outcome variable, time to death 
all-cause mortality, without the influence of confounding or adjusting variables. The 
Kaplan-Meier modelling indicated that there was a significant difference in probability 
of all-cause mortality between the tertiles of urinary cadmium (Figure 2), (log rank 
(Mantel-Cox) p = 0.011, Breslow (Generalised Wilcoxon) p = 0.010, Tarone-Ware p = 
0.010). Kaplan-Meier analysis was also run with the population stratified by smoking 
history (see Appendix C, Figures 6-7). In those who had never smoked, the plot 
identified that there were potential violations of proportionality between the tertiles as 
they interact and cross one another (Appendix C, Figure 6). Although there is some 
interaction and cross over between the lower and medium concentration groups in the 
ever smoked population plot, those with the highest concentrations can be seen to have 
a lower probability of survival and does not appear to violate proportionality (Appendix 
C, Figure 7). However, the trend tests have conflicting findings: log rank (Mantel-Cox), 
p = 0.030; Breslow (Generalized Wilcoxon), p = 0.147; Tarone-Ware, p = 0.069). 
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Figure 2. Kaplan-Meier plot of time until death between the observed urinary cadmium 
tertiles within the total population (N = 1359). 
A total of 532 participants (39.1%) died during the 15 year follow up period, 221 
(43.9%) of those participants were ever smokers and 309 (36.3%) never smokers. As 
the Kaplan-Meier plot identified a significant difference in the probability of all-cause 
mortality between the tertiles of urinary cadmium, a Cox proportional-hazards model 
was run to identify whether additional independent variables, identified as significant in 
the logistic regression analysis with all-cause mortality, reduced or removed the 
influence of cadmium on the time to death. As can be seen in the table below (Table 
15), after adjustment for confounders, increased urinary cadmium was not significantly 
associated with survival in the total population  (the survival plot had a large amount of 
interactions between the tertiles and can be found in Appendix D, Figures 8-9). 
However, when the analysis was stratified by smoking history, those in the highest 
urinary cadmium concentration group (> 0.255 µg/L) who had ever smoked were at 
statistically higher probability of dying during the 15 year follow up (HR = 1.638, 95% 
CI = 1.155-2.451), than those with lowest urinary cadmium concentrations (≤ 0.115 
µg/L) (plots can be found in Appendix D, Figures 12-13). Although a statistically 
significant relationship was identified in ever smokers, no such relationship was 
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identified in those who had never smoked (Table 15) (plots available in Appendix D, 
Figures 10-11). The adjusted hazard ratios for each population are presented in the 
Forest plot below (Figure 3).  
Table 15. Cox proportional-hazards for time until death within the total population (N = 
1359), and the never smoked (n = 851) and ever smoked populations (n = 501) for observed 
cadmium. 
  
  B Sig. 
Hazard 
Ratio 
95.0% CI for HR 
  Lower Upper 
Total population Low urinary Cd  .155    
 Medium urinary Cd .095 .447 1.100 .861 1.406 
 High urinary Cd .228 .058 1.257 .993 1.591 
 
Age at baseline .072 <.001 1.075 1.038 1.113 
 
Ever smoker .296 .003 1.345 1.108 1.633 
 
Diabetes .340 .049 1.404 1.001 1.969 
 
Hypertension .266 .010 1.305 1.066 1.598 
 
Low dose aspirin .260 .021 1.296 1.040 1.617 
 
Cystatin C .641 .003 1.899 1.249 2.887 
 
Prevalent CVD .325 .003 1.384 1.115 1.717 
      
Never Smoked Low urinary Cd  .756    
 Medium urinary Cd .096 .542 1.100 .809 1.497 
 High urinary Cd -.011 .946 .989 .724 1.352 
 Age .111 <.001 1.117 1.066 1.170 
 Diabetes .495 .035 1.640 1.036 2.597 
 Hypertension .463 .001 1.589 1.209 2.089 
 Low dose aspirin .350 .015 1.420 1.069 1.885 
 Cystatin C .760 .008 2.137 1.218 3.750 
 Prevalent CVD .057 .700 1.058 .793 1.412 
       
Ever Smoked Low urinary Cd  .011    
 Medium urinary Cd .149 .480 1.161 .767 1.756 
 High urinary Cd .520 .007 1.683 1.155 2.451 
 Age .033 .241 1.033 .978 1.091 
 Diabetes .079 .764 1.082 .647 1.811 
 Hypertension .071 .652 1.074 .789 1.461 
 Low dose aspirin .097 .591 1.102 .773 1.572 
 Cystatin C .421 .175 1.524 .829 2.800 
  Prevalent CVD .702 <.001 2.019 1.451 2.809 
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Figure 3. Forest plot which showing the hazard ratios, and lower and upper confidence 
intervals, for the analysis of all-cause mortality between the tertiles of observed cadmium, 
with extreme values included (N = 1059). 
The Cox proportional-hazards analysis for time until death (all cause mortality) was 
also repeated excluding participants with extreme values of urinary cadmium (urinary 
cadmium > 10 µg/L), and the findings are presented below (Table 16). Removal of 
these outliers did not substantially change the results. Similar to the previous Cox 
modelling, when the analysis was stratified by smoking history, ever smokers in the 
highest urinary cadmium concentration tertile were at significantly greater hazard of 
dying (HR = 1.683, 95% CI = 1.155-2.451) than those in the lowest tertile. The Forest 
plot below (Figure 4) illustrates the increased risk.  
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Table 16. Cox proportional-hazards for time until death within the total population (N = 
1359), and the never smoked (n = 851) and ever smoked populations (n = 501) for observed 
cadmium without those above 10 µg/L. 
  
  B Sig. 
Hazard 
Ratio 
95.0% CI for HR 
 
Lower Upper 
Total population Low urinary Cd  .146       
 Medium urinary Cd .097 .440 1.101 .862 1.408 
 High urinary Cd .232 .054 1.261 .996 1.597 
 
Age .072 .000 1.074 1.037 1.113 
 
Ever smoker .298 .003 1.347 1.109 1.635 
 
Diabetes .327 .058 1.387 .988 1.946 
 
Hypertension .269 .009 1.309 1.069 1.603 
 
Low dose aspirin .256 .023 1.292 1.036 1.613 
 
Cystatin C .626 .004 1.870 1.228 2.849 
 
Prevalent CVD .330 .003 1.391 1.121 1.727 
      
Never Smoked Low urinary Cd  .754       
 Medium urinary Cd .098 .531 1.104 .811 1.501 
 High urinary Cd -.007 .964 .993 .726 1.358 
 Age .110 .000 1.116 1.065 1.169 
 Diabetes .502 .032 1.652 1.043 2.617 
 Hypertension .468 .001 1.597 1.214 2.101 
 Low dose aspirin .358 .013 1.430 1.077 1.899 
 Cystatin C .726 .012 2.066 1.172 3.641 
 Prevalent CVD .063 .666 1.066 .799 1.422 
       
Ever Smoked Low urinary Cd  .011       
 Medium urinary Cd .149 .480 1.161 .767 1.756 
 High urinary Cd .520 .007 1.683 1.155 2.451 
 Age .038 .179 1.039 .983 1.097 
 Diabetes .073 .780 1.076 .645 1.794 
 Hypertension .071 .647 1.074 .791 1.458 
 Low dose aspirin .061 .739 1.063 .743 1.520 
 Cystatin C .415 .182 1.514 .823 2.783 
  Prevalent CVD .694 .000 2.002 1.440 2.784 
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Figure 4. Forest plot which shows the hazard ratios and lower and upper confidence 
intervals for the analysis of all-cause mortality between the tertiles of observed cadmium, 
with extreme values excluded. 
As Cystatin C was a major predictor of death, and a confounding variable, its presence 
in the models may mask the influence of the explanatory variable. Therefore to further 
investigate the relationship between tertiles of urinary cadmium and all-cause mortality, 
the models were re-run with Cystatin C was removed. Although the table is not 
presented in the results (Appendix B, Table 41), the Forest plot below (Figure 5) shows 
significant adjusted hazards ratio within the analysis. In the total population, those in 
highest urinary cadmium tertile had an adjusted HR of 1.279 (95% CI = 1.037-1.578) 
when compared with those in the lowest tertile, indicating that in the absence of 
adjustment for Cystatin C in the model, urinary cadmium was a significant influence on 
probability of survival over the 15 year follow up. As in the previous analysis including 
Cystatin C, ever smokers with urinary cadmium concentrations >0.255 µg/L had an 
increased probability of mortality during the follow up than those with concentrations ≤ 
0.115 µg/L (HR = 1.744, 95% CI = 1.245-2.445).  
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Figure 5. Forest plot which shows the hazard ratios and lower and upper confidence 
intervals for the analysis of all-cause mortality between the tertiles of observed cadmium, 
with extreme values included and Cystatin C removed. 
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Discussion  
Summary of Key Findings 
This longitudinal study of elderly Perth women identified that increased cadmium 
exposure, measured in urine, was associated with greater odds of several types of CVD, 
as well as death, over the 15-year follow up period. The findings indicated that there 
were positive relationships between urinary cadmium and all-cause mortality, heart 
failure, peripheral arterial disease and atherosclerotic vascular disease. An increased 
risk of mortality over the follow up period was also identified for those who had ever 
smoked and had urinary cadmium concentrations greater than 0.255 µg/L. The 
relationships, which were identified in this study, were found despite the relatively low 
urinary cadmium concentrations measured in this population. To our knowledge, this 
was the first study of its kind conducted in Australia.   
Urinary Cadmium 
Of the sixteen studies that were identified in the literature, which examined urinary 
cadmium in non-occupationally exposed populations, eight reported either an arithmetic 
mean (AM) or geometric mean (GM) for observed urinary cadmium, and two of these 
were in Australian populations (for details on all urinary cadmium studies, see 
Appendix E, Table 42). Hinwood et al. (2013) reported cadmium concentrations in 
pregnant Australian women, which were double the median found in this study (0.38 
µg/L compared with 0.18 µg/L), however, increased cadmium concentrations in 
pregnant women may not be unusual as low iron stores increase bioaccumulation of 
cadmium (Akesson et al., 2002). Furthermore, cadmium concentrations in another 
Australian study of older women found similar levels of urinary cadmium to this study 
(Callan et al., 2015). Six international studies reported observed urinary cadmium, of 
which five of six were greater than this study and ranged from 0.30 µg/L to 0.45 µg/L 
for GM and 0.36 µg/L to 0.72 µg/L for AM from (Health Canada, 2010; Navas-Acien et 
al., 2005; Peters et al., 2010; Sponder et al., 2014; Tellez-Plaza, Navas-Acien, 
Crainiceanu, Sharrett, & Guallar, 2010). One was consistent with the findings presented 
here (GM = 0.16 µg/L compared to 0.17 µg/L) (Centres for Disease Control and 
Prevention [CDC], 2015). These findings suggest that the urinary cadmium 
concentrations identified in this study were generally lower than other international 
populations.  
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There were thirteen studies which reported creatinine corrected concentrations of 
cadmium in urine and two of them were from Australian populations. Both of the 
Australian studies (Callan et al., 2015; Hinwood et al., 2013) reported concentrations 
less than found in this study (0.91 µg/g creatinine). Of the international studies, three 
reported GM of creatinine corrected urinary cadmium concentrations, which were 
greater than our study, and these ranged from 0.81 µg/g creatinine to 0.94 µg/g 
creatinine (Health Canada, 2010; Tellez-Plaza, Guallar, Howard, et al., 2013; Tellez-
Plaza, Jones, Dominguez-Lucas, Guallar, & Navas-Acien, 2013). The remaining 
international studies reported creatinine corrected urinary cadmium concentrations that 
were less than our findings, ranging from 0.22 µg/g creatinine to 0.77 µg/g creatinine 
(Centres for Disease Control and Prevention [CDC], 2015; Everett & Frithsen, 2008; 
Fagerberg, Bergström, Borén, & Barregard, 2013; Health Canada, 2010; Mendy, 
Gasana, & Vieira, 2012; Menke et al., 2009; Shirai, Suzuki, Yoshinaga, & Mizumoto, 
2010; Tellez-Plaza, Guallar, Fabsitz, et al., 2013; Tellez-Plaza, Guallar, Howard, et al., 
2013; Tellez-Plaza et al., 2010; Tellez-Plaza et al., 2012). However, as previously 
described, urinary creatinine concentrations were considered dilute and below the 
threshold acceptable for creatinine adjustment of urinary analytes (WHO, 1996) and as 
such, only the observed cadmium variable was used in the analysis, to avoid over 
adjustment of the urinary cadmium concentrations.  
Discussion of Results 
All-Cause Mortality  
In this representative sample population of elderly women from Perth, it was identified 
that ever smokers with high urinary cadmium concentrations (> 0.255 µg/L) had 
increased odds all-cause mortality. No association was identified in either the total 
population or never smokers, in any of the analyses and these findings are consistent 
with of two large longitudinal US studies (Menke et al., 2009; Tellez-Plaza et al., 2012). 
However, when Cystatin C, which was identified as a strong confounding variable, was 
removed from the analysis, participants with urinary cadmium concentrations greater 
than 0.255 µg/L were at significantly greater risk of death during the follow-up period. 
Increased urinary cadmium and an increase in mortality risk was also identified in one 
of the international studies, which sampled a population of Native Americans (Tellez-
Plaza, Guallar, Howard, et al., 2013). Even though the population in this US study was 
younger, the geometric mean of urinary cadmium was much greater than found in this 
 Association between Cadmium and CVD  
 
45 
study and the rate of mortality was 1.8 times higher (Appendix A, Table 17). Taken 
together these findings suggest a relationship between increasing urinary cadmium and 
an increased risk of mortality in women. 
Atherosclerotic Vascular Disease 
There were no studies identified in the literature that examined the relationship between 
urinary cadmium and the risk of atherosclerotic vascular disease. This gap in the 
literature exists despite the relative importance and detrimental effect of atherosclerotic 
vascular disease on population health (AIHW, 2011). Atherosclerotic vascular disease is 
a combined measure of coronary heart disease, cerebrovascular accident, heart failure 
and peripheral arterial disease, therefore it might be anticipated that if an association 
between urinary cadmium and CVD did exist, it would be identified using 
atherosclerotic vascular disease as the outcome. Consistent with this notion, the findings 
of this study did identify a relationship between urinary cadmium and atherosclerotic 
vascular disease, with an increase of urinary cadmium concentrations by one unit 
resulting in an increase in the odds of death by atherosclerotic vascular disease by 1.156 
times (95% CI = 1.015-1.315). These findings are similar to three studies identified in 
the literature that reported positive associations between increased urinary cadmium and 
the risk of cardiovascular disease mortality, although none specifically used 
atherosclerotic vascular disease as the outcome (Menke et al., 2009; Tellez-Plaza, 
Guallar, Howard, et al., 2013; Tellez-Plaza et al., 2012).  
Peripheral Arterial Disease  
Evidence examining the relationship between increasing urinary cadmium and increased 
risk of peripheral arterial disease is far from definitive. In this study it was identified 
that ever smokers with high urinary cadmium levels (> 0.255 µg/L compared to ≤ 0.155 
µg/L) were at greater odds of peripheral arterial disease event, which are the combined 
outcomes of peripheral arterial disease hospitalisation and multiple causes of death 
including peripheral arterial disease. When comparing participants with urinary 
cadmium concentrations of 0.115-0.255 µg/L to those with less than 0.155 µg/L, those 
who had never smoked were also at increased odds of peripheral arterial disease event. 
In this study the prevalence or incidence of peripheral arterial disease was lower than 
reported by other international studies  (4.8% compared to 13.7%, 6.8%, 9.4% and 
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7.2%) (Fagerberg et al., 2013; Navas-Acien et al., 2005; Tellez-Plaza, Guallar, Fabsitz, 
et al., 2013; Tellez-Plaza et al., 2010).  
Although no relationship between increasing urinary cadmium and the risk of peripheral 
arterial disease incidence was identified in this study, all four of the studies identified in 
the literature did report positive associations. One such study, conducted by Tellez-
Plaza et al. (2010), only reported a positive relationship in men, and that in women a U-
shaped dose-relationship existed, where comparisons of quintiles three and one and four 
and one, resulted in a significantly negative association between urinary cadmium and 
the incidence of peripheral arterial disease (Appendix A, Table 17). The authors noted 
that two-thirds of the urine samples could not be located and the missing values were 
calculated using a prediction model (Tellez-Plaza et al., 2010), which may have 
adversely affected the outcome of the study. Fagerberg et al. (2013), using an elderly 
cohort of Swedish women (N = 489), found a significantly increased incidence of 
peripheral arterial disease when they compared the highest and lowest urinary cadmium 
tertiles (≥ 0.46 µg/g creatinine compared to < 0.29 µg/g creatinine). However, the 
Swedish study was cross-sectional, limiting the ability to determine a cause-and-effect 
relationship, and it had a much smaller sample population than this study, which means 
that it is more likely than this study to identify the true relationship. Furthermore, 
models were not adjusted for many of the cardiovascular risk factors in the Swedish 
study, which may have reduced or removed the significant effect size.   
The third study, which also reported a positive relationship between increasing urinary 
cadmium and peripheral arterial disease incidence was conduced in an NHANES 
population (N = 790, ≥ 40 years) (Navas-Acien et al., 2005). However, as the study 
design was cross-sectional, the sample size was much smaller, and the genders were 
modelled together, which may have different risks as previously highlighted by Tellez-
Plaza et al. (2010), and generalisability, and comparability to the findings in this study 
may be limited. In the only longitudinal study identified in the literature (Native 
Americans, N = 2864, 45-74 years), the risk of developing peripheral arterial disease 
was significantly greater in participants with the highest urinary cadmium levels (> 1.23 
µg/g creatinine compared to ≤ 0.71 µg/g creatinine)(Tellez-Plaza, Guallar, Fabsitz, et 
al., 2013). Although the US study has strong external validity, due its longitudinal 
design and large sample size, the follow-up period was shorter, the study population 
was younger, and yet the incidence of peripheral arterial disease was almost double that 
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reported here (9.4% compared to 4.8%) (Appendix A, Table 17). Furthermore, the 
geometric mean for urinary cadmium concentrations in the US study was more than five 
times the level reported in this study (1.03 µg/L compared to 0.17 µg/L). These 
descriptors indicate that the health status of this Native American population is much 
lower than this population, which may have led to the identification of the relationship. 
Finally, as none of the studies identified in the literature examined peripheral arterial 
disease causing death, it was not possible to compare our findings for this outcome 
directly to any of the other studies.   
Heart Failure 
Heart failure is one of the four major CVD and in 2007-2008 there were an estimated 
277,800 Australians hospitalised due to heart failure, with over a third of them being 
over the age of 75 (AIHW, 2011). In this study, a positive relationship was identified 
between increasing urinary cadmium and increased odds of multiple causes of death, 
heart failure in the total population and in never smokers. A similar association was 
identified with heart failure event, in both the total population and in ever smokers. 
There were three studies identified in the literature that examined the relationship 
between increasing urinary cadmium and heart failure, all of which measured heart 
failure incidence. One such study, which was longitudinal and sampled a Native 
American population (for descriptors see Appendix A, Table 17), reported a positive 
relationship between urinary cadmium and the risk of heart failure incidence in their 
total population, although the relationship was not significant in the analysis of females, 
or never smokers (Tellez-Plaza, Guallar, Howard, et al., 2013), which agree with the 
findings of this study.  
Findings in the other two studies suggested that there was a relationship between 
increasing urinary cadmium and increased risk of heart failure incidence (Peters et al., 
2010; Tellez-Plaza et al., 2012). However, as both studies only modelled the total 
population, it was not possible to identify if the relationship was gender specific. 
Furthermore, although both of the sample populations used in the US studies were much 
younger than this study, they both reported geometric means of urinary cadmium that 
were much greater than seen here (Appendix A, Table 17), which could suggest that 
they were already at increased risk. None of the studies identified in the literature 
examined the relationship between increasing urinary cadmium and the odds of heart 
failure mortality, or heart failure mortality and incidence, which were identified as 
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significant in this study, and therefore it is recommended that future studies consider 
these outcomes.  
Coronary Heart Disease 
No relationship between urinary cadmium and coronary heart disease risk was identified 
in any of the analyses in this study. In contrast, four of the five studies identified in the 
literature disagreed with these findings, suggesting that increasing urinary cadmium was 
associated with an increased risk of either coronary heart disease incidence or mortality 
(Everett & Frithsen, 2008; Mendy et al., 2012; Tellez-Plaza, Guallar, Howard, et al., 
2013; Tellez-Plaza et al., 2012). However, even though the sample size of all four of 
these studies was larger than this study, most of the studies were not longitudinal and 
they were all sampled from US populations (Appendix A, Table 17). In the fifth study, 
also from the US, the authors reported an inverse relationship between urinary cadmium 
and coronary heart disease mortality, where high levels of urinary cadmium had a 
protective effect (Menke et al., 2009).  
Although most of the studies identified a relationship between increasing urinary 
cadmium and the odds of coronary heart disease, all five were conducted in US 
populations (four using NHANES samples), which may limit the ability to generalise 
the findings to populations outside the US. The rates of the coronary heart disease 
incidence and mortality reported in the other studies were comparable to the rate in this 
study, although only two of the studies presented the number of cases (Appendix A, 
Table 17). It is, however, recommended that further research is conducted in other 
Australian populations and other populations internationally, to confirm the relationship 
between urinary cadmium and coronary heart disease.  
Cerebrovascular Accident/Stroke  
Similar to coronary heart disease, this study also found that there were no significant 
associations between urinary cadmium concentrations and the odds of cerebrovascular 
accident, multiple causes of death cerebrovascular accident or cerebrovascular event. 
The review of the literature identified that no studies have ever been published, which 
have used cerebrovascular accident mortality or cerebrovascular event as an end-point. 
However, three of the four studies identified in the literature that examined incidence of 
stroke and urinary cadmium reported a positive association between the two variables 
(Mendy et al., 2012; Peters et al., 2010; Tellez-Plaza et al., 2012), whilst the fourth 
 Association between Cadmium and CVD  
 
49 
study reported no relationship (Tellez-Plaza, Guallar, Howard, et al., 2013). Also 
similar to coronary heart disease, all four of the studies were conducted in US 
populations (three using NHANES samples) (Appendix A, Table 17). Two of those 
studies that reported a relationship, also reported geometric means of unadjusted urinary 
cadmium concentrations which were twice the concentration found in this study, even 
though their populations were much younger (Appendix A, Table 17) (Mendy et al., 
2012; Peters et al., 2010). Although different lifestyle factors would also contribute to 
variations in cadmium concentrations between populations, the findings of this study 
suggest that US populations may have greater cadmium exposure. 
Implications  
Policy  
Ever smokers were at increased risk of more health outcomes than never smokers and 
they also had significantly greater urinary cadmium concentrations. Even though 
smoking rates have almost halved in people 18 years and older since the urine was 
collected in 1998 (22.7% in 1998 to 13.3% in 2013) (Department of Health, 2015), one 
in every eight people continues to smoke, and therefore, there is an opportunity for 
further decreases As. A number of validated methods can be considered to achieve this 
reduction in smoking, and in turn cadmium exposure (Australian Medical Association, 
2005; Public Health Association of Australia, 2014). These include: increasing taxes on 
cigarette purchases, public health initiatives that focus on the risk factors associated 
with smoking, and lobbying tobacco companies to reduce cadmium concentrations in 
their cigarettes. Creating policy to accomplish this goal would require consultation and 
comment from a variety of stakeholders such as the Department of Health, tobacco 
lobbyists, anti-smoking advocate groups, the Australian Medical Association and the 
Public Health Association of Australia.  
Since the urine was collected, the National Cadmium Management Committee was 
established. The committee aimed to maintain safe concentrations of cadmium in 
Australian soil through the reduction of its use in fertilisers and other agricultural 
processes (National Cadmium Management Committee, 2007). As such, policy aimed 
at reducing cadmium exposure in Australia has already been developed and 
implemented. However, as it takes many years for cadmium to leave the soil (Mann et 
al., 2002), it may be some time before we see reductions of urinary cadmium 
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concentrations. To minimise exposure, it is recommended that people eat a variety of 
fresh fruits and vegetables.  
Practice and Methodology  
In general, studies that aim to analyse metals in urine, the first morning void is collected 
and then refrigerated or frozen (≤ -20 °C) until analysis, as this is the preferred method 
to measure substance, such as heavy metals and hormones, in a concentrated solution 
(International Society for Biological and Environmental Repositories [ISBER], 2008). 
However, as the original calcium supplementation and bone health study collected spot 
urine samples at morning appointments, it resulted in very dilute measurements, as 
evident by the number of samples (54.5%) that were below the threshold, which is 
acceptable for adjustment of urinary analytes (< 0.2 g/L creatinine). Due to the dilution 
and potential over adjustment of the samples it was considered inappropriate to use the 
creatinine corrected concentrations in the statistical analysis. Therefore, any future 
studies should consider following procedures outlined by ISBER for first morning 
voids, if they are considering analysing metals exposure at any stage in their research. 
Limitations and Critical Reflection 
This study has many strengths; including its longitudinal design, large representative 
sample, and access to the comprehensive data linkage system, which has been verified 
by more than 250 papers (Bass et al., 2008). However, like any study, it also has 
limitations. Firstly, although sampling urinary cadmium is a good predictor of long-
term exposure, measuring it only once may result in measurement error due to the 
potential variation of concentrations within the individual at any given time (Menke et 
al., 2009; Tellez-Plaza et al., 2012). This could have resulted in an underestimation of 
associations with the heath outcomes. Secondly, as half of the participants received 
calcium supplements during the 5-year CAIFOS study, it was initially thought that this 
treatment variable would be adjusted for during the statistical analysis. However, as the 
researcher did not have access to these data, adjustment was not possible. The effect of 
the calcium supplements on the risk of CVD was measured in this population, and the 
results indicated that for those who received supplements there was no significant 
increase in risk (Lewis et al., 2011). Thirdly, as the urine collected was not first void, it 
meant that the researchers were unable to adjust for creatinine, which may have affected 
their ability to identify the relationship between urinary cadmium and CVD. Finally, 
given the importance of smoking, access to more detailed smoking-related covariates, 
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such as pack-years smoking or serum cotinine, which many of the other studies 
reported, may have helped further adjust the analysis and improve the internal validity 
of the study (Creswell, 2009). 
Further Research  
This study found that, even though urinary cadmium concentrations were generally low, 
an association between low-level environmental cadmium exposure and increased risk 
of mortality and CVD was present. As such, it is recommended that studies with similar 
designs be undertaken in other Australian populations to confirm the findings of this 
study. In order to facilitate this task, it is suggested that a sample, which is 
representative of the national population (similar to the NHANES system), be recruited. 
This would improve the external validity of the findings. Furthermore, if the sampling is 
planned correctly, the data collected could be used for a multitude of projects, thus 
reducing the overall financial burden associated with undertaking research. 
Additionally, if future longitudinal studies developed hazard ratios at regular intervals 
throughout the follow up period (for example, every 2, 5 or 10 years), it would help 
identify if the hazard changes over time, and if it does, when participants would be at 
the greatest risk (Bradburn et al., 2003). Furthermore, multiple measurements of 
confounding variables throughout the follow up period would also increase the 
predictive power of the final model (Clark et al., 2003b). Future studies could also 
include data of all CVD outcomes (ICD-10-AM, I00-I99), as this would make it 
comparable to many of the international studies that have considered this. Although this 
study identified that Cystatin C was a significant confounding variable in many of the 
health outcomes, most of the international literature did not even adjust for it. These 
findings add the emerging literature suggesting that Cystatin C may be a risk factor for 
CVD (Angelidis et al., 2013; Cepeda et al., 2010), and as such, it is recommended that 
future studies consider measuring it. 
Finally, given the risks identified in this study, it is important to investigate if cadmium 
exposure has changed since the samples were collected in 1998, as this would help 
determine whether the risk of CVD or mortality has also changed. When comparing the 
findings of this study, to urine samples collected in 2011 from a similar population 
(Callan et al., 2015), it could be suggested that urinary cadmium concentrations have 
not changed in Western Australia. However, findings of Riederer, Belova, George, and 
Anastas (2013), who examined how urinary cadmium concentrations have changed in 
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the US NHANES population in the past two decades, indicated that exposure has 
decreased, as evidenced by lower concentrations of cadmium in urine, with the 
reduction in smoking rates a suggested cause for these changes. Even if this is also the 
case in Australia, it must be first identified, and then researchers should continue to 
monitor sources of cadmium exposure, as well as relative cadmium concentrations in 
humans, because as this study shows, even at low levels of exposure this metal can 
increase the risk of disease.  
Conclusion. 
Given the importance and prevalence of CVD within the Australian population, as well 
as the relationship between low-level cadmium exposure and CVD outcomes identified 
in international studies, it was the aim of this research to examine if that relationship 
existed in an Australian population. Even though the research revealed that urinary 
cadmium concentrations in this population were generally lower than others, it also 
found that participants with higher urinary cadmium concentrations were at 
significantly greater odds of several CVD outcomes, as well as all-cause mortality. 
These outcomes included: increased odds of atherosclerotic vascular disease and heart 
failure in the total population, increased odds of heart failure and peripheral arterial 
disease in those who have never smoked, and increased odds of death, heart failure and 
peripheral arterial disease in ever smokers.  
These associations were comparable to findings reported in other studies. Interestingly, 
most of the studies identified in the literature also reported positive relationships 
between urinary cadmium and coronary heart disease and stroke, which were not 
evident in this population. However, the lower rates of disease and death within this 
cohort of elderly women from Perth, and the fact that 82% of the research that 
examined urinary cadmium concentrations and the risk CVD or mortality was 
conducted in US populations, may help explain this discrepancy. Moreover, no other 
studies were identified in the literature examined the relationship in an Australian 
population and as such, it is recommended that similar cadmium exposure and disease 
risk studies be conducted in other Australian populations in order to confirm the 
findings of this study. In conclusion, this study disproves the null hypothesis and 
suggests that, even at low levels of exposure, cadmium is associated with significantly 
increased odds of CVD and mortality in an elderly cohort of women from Perth.  
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Appendix B: Logistic Regressions with Non-Significant 
Urinary Cadmium 
Table 18. Logistic regression for death by atherosclerotic vascular disease (ASVD) within 
the total population (N = 1359), and the never smoked (n = 851) and ever smoked 
populations (n = 501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .425       
 Medium urinary Cd .050 .841 1.052 .643 1.720 
 High urinary Cd .283 .235 1.327 .831 2.119 
 Age .120 .001 1.128 1.052 1.209 
 
Hypertension .616 .003 1.851 1.232 2.781 
 
Low dose aspirin .478 .036 1.613 1.033 2.520 
 
LDLC .005 .040 1.005 <.001 1.010 
 
Cystatin C 1.226 .004 3.407 1.488 7.801 
 
Prevalent ASVD .984 <.001 2.675 1.599 4.476 
 
Constant -13.315 <.001 <.001         
Never Smoked Low urinary Cd  .404    
 
Medium urinary Cd .322 .180 1.380 .862 2.211 
 
High urinary Cd .144 .560 1.154 .713 1.870 
 
Age .200 <.001 1.221 1.136 1.313 
 
BMI .044 .037 1.045 1.003 1.090 
 
Hypertension .680 .002 1.973 1.294 3.009 
 
Low dose aspirin .650 .003 1.916 1.244 2.950 
 
eGFR -.008 .267 .992 .977 1.006 
 
Prevalent ASVD .542 .046 1.719 1.009 2.926 
 
Constant -18.070 <.001 <.001         
Ever Smoked Low urinary Cd  .386    
 
Medium urinary Cd .216 .496 1.241 .666 2.313 
 
High urinary Cd .411 .172 1.509 .836 2.722 
 
Age .007 .875 1.007 .924 1.097 
 
BMI .042 .085 1.043 .994 1.094 
 
Hypertension .079 .752 1.082 .665 1.759 
 
Low dose aspirin .412 .154 1.509 .857 2.657 
 
eGFR -.018 .044 .982 .965 1.000 
 
Prevalent ASVD 1.325 <.001 3.763 2.028 6.982 
 Constant -2.263 .525 .104     
Nagelkerke R2 = 14.9%, 16.3% and 15.0%; Correct case classification = 81.5%, 81.1% and 78.1%. 
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Table 19. Logistic regression for atherosclerotic vascular disease (ASVD) hospitalisation 
within the total population (N = 1359), and the never smoked (n = 851) and ever smoked 
populations (n = 501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .056 .401 1.058 .927 1.207 
 Age .076 .006 1.079 1.022 1.139 
 Ever smoked .337 .027 1.401 1.039 1.889 
 Hypertension .603 <.001 1.827 1.365 2.446 
 
Low dose aspirin .368 .038 1.445 1.020 2.047 
 
eGFR -.015 .006 .985 .974 .996 
 
HDLC -.011 .034 .989 .979 .999 
 
Constant -5.220 .016 .005         
Never Smoked Urinary cadmium -.041 .573 .959 .831 1.108 
 
Age .069 .027 1.072 1.008 1.140 
 
Hypertension .636 <.001 1.889 1.336 2.669 
 
Cystatin C 1.761 <.001 5.818 2.464 13.736 
 
Constant -8.249 <.001 <.001         
Ever Smoked Urinary cadmium .130 .196 1.139 .935 1.388 
 
Age .041 .285 1.042 .967 1.122 
 
Hypertension .400 .061 1.492 .982 2.267 
 
Cystatin C .691 .131 1.997 .815 4.894 
 Constant -4.175 .140 .015     
Nagelkerke R2 = 8.5%, 9.3% and 3.4%; Correct case classification = 68.4%, 68.6% and 60.6%. 
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Table 20. Logistic regression for atherosclerotic vascular disease (ASVD) hospitalisation 
within the total population (N = 1359), and the never smoked (n = 851) and ever smoked 
populations (n = 501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .597       
 Medium urinary Cd -.028 .878 .972 .681 1.389 
 High urinary Cd .139 .437 1.150 .809 1.633 
 Age .076 .006 1.079 1.022 1.139 
 
Ever smoked .335 .028 1.398 1.037 1.886 
 
Hypertension .593 <.001 1.810 1.350 2.425 
 
Low dose aspirin .373 .036 1.451 1.024 2.057 
 
eGFR -.015 .006 .985 .974 .996 
 
HDLC -.011 .035 .989 .980 .999 
 
Constant -5.330 .014 .005         
Never Smoked Low urinary Cd  .563    
 
Medium urinary Cd -.159 .444 .853 .569 1.281 
 
High urinary Cd -.216 .307 .806 .532 1.219 
 
Age .071 .024 1.074 1.009 1.142 
 
Hypertension .607 .001 1.836 1.293 2.606 
 
Statin use .490 .022 1.632 1.074 2.480 
 
Cystatin C 1.784 <.001 5.952 2.513 14.100 
 
Constant -8.277 <.001 <.001         
Ever Smoked Low urinary Cd  .246    
 
Medium urinary Cd .462 .094 1.587 .924 2.727 
 
High urinary Cd .279 .291 1.322 .787 2.218 
 
Age .042 .274 1.043 .967 1.124 
 
Hypertension .379 .083 1.461 .952 2.244 
 
Statin use .323 .237 1.382 .808 2.362 
 
Cystatin C .690 .133 1.994 .810 4.907 
 Constant -4.782 .094 .008     
Nagelkerke R2 = 8.6%, 10.4% and 4.2%; Correct case classification = 67.4%, 68.7% and 60.8%. 
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Table 21. Logistic regression for atherosclerotic vascular disease (ASVD) event within the 
total population (N = 1359), and the never smoked (n = 851) and ever smoked populations 
(n = 501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .018 .744 1.018 .914 1.134 
 Age .102 <.001 1.107 1.058 1.159 
 BMI .037 .006 1.037 1.010 1.065 
 Ever smoked .408 .001 1.504 1.174 1.926 
 
Hypertension .598 <.001 1.818 1.420 2.327 
 
Low dose aspirin .571 <.001 1.770 1.325 2.366 
 
eGFR -.016 .001 .984 .975 .993 
 
Constant -8.461 <.001 <.001         
Never Smoked Urinary cadmium -.051 .478 .950 .825 1.094 
 
Age .109 <.001 1.115 1.050 1.185 
 
Hypertension .720 <.001 2.055 1.471 2.870 
 
Low dose aspirin .505 .010 1.656 1.127 2.435 
 
Cystatin C 1.473 .001 4.361 1.859 10.234 
 
Constant -10.763 <.001 <.001         
Ever Smoked Urinary cadmium .173 .088 1.189 .975 1.451 
 
Age .036 .359 1.036 .960 1.118 
 
Hypertension .310 .145 1.363 .899 2.067 
 
Low dose aspirin .662 .013 1.939 1.152 3.264 
 
Cystatin C 1.095 .024 2.988 1.155 7.732 
 Constant -3.831 .181 .022   
Nagelkerke R2 = 11.9%, 12.7% and 7.5%; Correct case classification = 64.0%, 64.1% and 61.1%. 
 
 
Table 22. Logistic regression for heart failure within the total population (N = 1359), and 
the never smoked (n = 851) and ever smoked populations (n = 501), for log transformed 
urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .081 .398 1.084 .899 1.307 
BMI .047 .025 1.048 1.006 1.092 
Hypertension .985 <.001 2.679 1.594 4.501 
Cystatin C 1.701 <.001 5.477 2.412 12.438 
 
Constant -6.034 <.001 .002         
Never Smoked Urinary cadmium .052 .642 1.054 .845 1.315 
 
Hypertension 1.096 .001 2.993 1.580 5.671 
Cystatin C 1.918 <.001 6.810 2.375 19.525 
 
Constant -4.999 <.001 .007         
Ever Smoked Urinary cadmium .200 .268 1.221 .857 1.740 
 
Hypertension 1.035 .020 2.814 1.174 6.745 
 
Cystatin C 2.029 .002 7.609 2.119 27.318 
 Constant -5.085 <.001 .006     
Nagelkerke R2 = 10.4%, 9.8% and 9.8%; Correct case classification = 90.7%, 91.6% and 89.8% 
 	  
 Association between Cadmium and CVD  
 
67 
Table 23. Logistic regression for heart failure within the total population (N = 1359), and 
the never smoked (n = 851) and ever smoked populations (n = 501), for tertiles of 
increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .760       
Medium urinary Cd .171 .541 1.187 .686 2.053 
High urinary Cd .187 .491 1.205 .708 2.051 
BMI .048 .024 1.049 1.006 1.093 
 
Hypertension .985 <.001 2.678 1.592 4.504 
 
Cystatin C 1.689 <.001 5.415 2.379 12.323 
 
Constant -6.302 <.001 .002         
Never Smoked Low urinary Cd  .950    
 
Medium urinary Cd .034 .918 1.035 .538 1.991 
 
High urinary Cd .103 .753 1.108 .584 2.104 
 
Hypertension 1.094 .001 2.987 1.573 5.674 
 
Cystatin C 1.924 <.001 6.851 2.380 19.724 
 
Constant -5.143 <.001 .006         
Ever Smoked Low urinary Cd  .556    
 
Medium urinary Cd .533 .315 1.705 .602 4.828 
 
High urinary Cd .499 .327 1.648 .607 4.476 
 
Hypertension 1.035 .020 2.816 1.175 6.748 
 
Cystatin C 1.985 .002 7.280 2.022 26.212 
 Constant -5.737 <.001 .003     
Nagelkerke R2 = 10.4%, 9.8% and 9.8%; Correct case classification = 90.7%, 90.3% and 91.6% 
 	  
Table 24. Logistic regression for peripheral arterial disease within the total population (N 
= 1359), and the never smoked (n = 851) and ever smoked populations (n = 501), for log 
transformed urinary cadmium concentrations. 
    
B Sig. Odds Ratio 
95% OR 
    Lower Upper 
Total 
Population 
Urinary cadmium .148 .250 1.160 .901 1.492 
Ever Smoker .776 .007 2.174 1.232 3.836 
Hypertension .657 .042 1.928 1.023 3.636 
Cystatin C 1.439 .006 4.216 1.520 11.688 
Constant -5.110 <.001 .006     
       
Never Smoked Urinary cadmium .101 .532 1.106 .805 1.520 
Diabetes 1.683 <.001 5.380 2.150 13.458 
Hypertension .980 .037 2.664 1.063 6.674 
Constant -4.046 <.001 .017   
       
Ever Smoked Urinary cadmium .216 .202 1.241 .891 1.729 
Diabetes -.323 .670 .724 .164 3.190 
Hypertension .399 .298 1.491 .703 3.161 
Constant -2.549 <.001 .078     
Nagelkerke R2 = 6.5%, 7.6% and 1.4%; Correct case classification = 95.1%, 96.6% and 93.4% 
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Table 25. Logistic regression for peripheral arterial disease event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. Odds Ratio 
95% OR 
    Lower Upper 
Total Population Urinary cadmium .164 .158 1.178 .938 1.481 
Smoked Ever .672 .010 1.958 1.171 3.271 
Hypertension .691 .019 1.996 1.122 3.554 
Cystatin C 1.331 .006 3.783 1.460 9.802 
Constant -4.704 <.001 .009     
       
Never Smoked Urinary cadmium .100 .487 1.105 .834 1.463 
Diabetes  1.691 <.001 5.427 2.376 12.400 
Hypertension 1.147 .007 3.149 1.359 7.297 
Constant -3.892 <.001 .020          
Ever Smoked Urinary cadmium .250 .112 1.284 .944 1.746 
Diabetes  -.526 .485 .591 .135 2.585 
Hypertension .416 .242 1.515 .756 3.039 
Constant -2.319 <.001 .098     
Nagelkerke R2 = 6.3%, 9.0% and 1.9%; Correct case classification = 94.0%, 95.5% and 92.2% 
 	  
Table 26. Logistic regression for multiple cause death including peripheral arterial disease 
within the total population (N = 1359), and the never smoked (n = 851) and ever smoked 
populations (n = 501), for log transformed urinary cadmium concentrations. 
    
B Sig. Odds Ratio 
95% OR 
    Lower Upper 
Total Population Urinary cadmium -.025 .910 .976 .638 1.493 
Age .231 .008 1.260 1.062 1.495 
Diabetes 1.607 .006 4.989 1.572 15.827 
Constant -22.170 .001 <.001          
Never Smoked Urinary cadmium -.095 .743 .909 .515 1.605 
Aspirin 1.841 .011 6.300 1.515 26.191 
Cystatin C 2.233 .024 9.332 1.338 65.074 
Constant -7.819 <.001 <.001          
Ever Smoked Urinary cadmium .336 .402 1.400 .637 3.075 
Aspirin .569 .520 1.766 .313 9.976 
Cystatin C -1.019 .617 .361 .007 19.649 
Constant -2.756 .217 .064   
Nagelkerke R2 = 7.4%, 14.5% and 2.4%; Correct case classification = 98.7%, 98.5% and 98.5% 
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Table 27. Logistic regression for multiple cause death including peripheral arterial disease 
within the total population (N = 1359), and the never smoked (n = 851) and ever smoked 
populations (n = 501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. Odds Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .756       
 Medium urinary Cd .357 .549 1.429 .444 4.596 
 High urinary Cd -.033 .958 .967 .275 3.399 
 Age .229 .009 1.257 1.059 1.492 
 
Diabetes 1.620 .006 5.051 1.585 16.091 
Constant -22.098 .001 <.001          
Never Smoked Low urinary Cd  .338     Medium urinary Cd .178 .788 1.195 .326 4.383 
 
High urinary Cd -1.444 .194 .236 .027 2.084 
Age .269 .019 1.309 1.045 1.640 
 Diabetes 2.122 .002 8.349 2.236 31.179 
 Constant -25.033 .005 <.001          
Ever Smoked Low urinary Cd  .837    
 
Medium urinary Cd 16.811 .996 19992030.741 0.000  
 
High urinary Cd 17.332 .996 33681441.664 0.000  
 
Age .132 .348 1.141 .866 1.505 
 
Diabetes -16.730 .998 <.001 0.000  
 Constant -31.130 .993 <.001     
Nagelkerke R2 = 7.7%, 16.5% and 9.9%; Correct case classification = 98.7%, 98.7% and 98.8% 
 
 
Table 28. Logistic regression for cerebrovascular accident (CVA) within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .001 .988 1.001 .861 1.164 
Low dose aspirin .695 <.001 2.004 1.394 2.880 
eGFR -.013 .040 .987 .975 .999 
Constant -1.223 .006 .294          
Never Smoked Urinary cadmium -.019 .840 .981 .816 1.180 
 
Age .109 .005 1.115 1.033 1.204 
 
Low dose aspirin .850 <.001 2.340 1.491 3.672 
 
Constant -10.486 <.001 <.001         
Ever Smoked Urinary cadmium .004 .972 1.004 .790 1.277 
 
Age -.066 .199 .937 .847 1.035 
 
Low dose aspirin .516 .086 1.676 .930 3.021 
 Constant 2.975 .435 19.582     
Nagelkerke R2 = 2.8%, 5.0% and 1.4%; Correct case classification = 87.0%, 88.0% and 86.1%. 
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Table 29. Logistic regression for cerebrovascular accident (CVA) within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .979       
Medium urinary Cd -.042 .844 .959 .635 1.450 
High urinary Cd -.009 .967 .991 .658 1.495 
Low dose aspirin .695 <.001 2.003 1.394 2.879 
 
eGFR -.013 .039 .987 .975 .999 
 
Constant -1.201 .008 .301         
Never Smoked Low urinary Cd  .882    
 
Medium urinary Cd -.123 .638 .884 .530 1.476 
 
High urinary Cd -.017 .949 .983 .589 1.642 
 
Age .108 .006 1.114 1.032 1.203 
 
Low dose aspirin .847 <.001 2.333 1.486 3.663 
 
Constant -10.348 <.001 <.001         
Ever Smoked Low urinary Cd  .934    
 
Medium urinary Cd -.108 .747 .897 .466 1.730 
 
High urinary Cd -.106 .741 .900 .480 1.686 
 
Age -.066 .195 .936 .847 1.035 
 
Low dose aspirin .521 .083 1.684 .934 3.037 
 Constant 3.083 .420 21.819     
Nagelkerke R2 = 2.8%, 5.0% and 1.5%; Correct case classification = 87.0%, 88.0% and 86.1%. 
 
 
Table 30. Logistic regression for cerebrovascular accident (CVA) event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .003 .958 1.003 .883 1.140 
Hypertension .390 .011 1.476 1.094 1.992 
Low dose aspirin .631 <.001 1.879 1.367 2.583 
Constant -1.962 <.001 .141          
Never Smoked Urinary cadmium -.037 .661 .964 .819 1.135 
 
Age .127 <.001 1.136 1.062 1.215 
 
Hypertension .477 .018 1.612 1.085 2.394 
 
Low dose aspirin .521 .015 1.684 1.107 2.564 
 
Constant -11.753 <.001 <.001         
Ever Smoked Urinary cadmium -.010 .929 .990 .800 1.226 
 
Age -.079 .082 .924 .845 1.010 
 
Hypertension .229 .340 1.257 .786 2.011 
 
Low dose aspirin .689 .009 1.993 1.184 3.355 
 Constant 4.139 .221 62.727     
Nagelkerke R2 = 2.8%, 5.5% and 3.1%; Correct case classification = 82.9%, 83.9% and 81.1%. 
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Table 31. Logistic regression for cerebrovascular accident (CVA) event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .998       
Medium urinary Cd .005 .977 1.005 .708 1.426 
High urinary Cd -.007 .969 .993 .701 1.407 
Hypertension .390 .011 1.478 1.095 1.994 
 
Low dose aspirin .631 <.001 1.879 1.367 2.583 
 
Constant -1.968 <.001 .140   Never Smoked Low urinary Cd  .913    
 
Medium urinary Cd .025 .914 1.025 .655 1.604 
 
High urinary Cd -.074 .753 .928 .584 1.475 
 
Age .127 <.001 1.135 1.061 1.215 
 
Hypertension .479 .018 1.615 1.087 2.399 
 
Low dose aspirin .522 .015 1.685 1.107 2.566 
 
Constant -11.642 <.001 <.001   Ever Smoked Low urinary Cd  .763    
 
Medium urinary Cd -.221 .462 .802 .445 1.444 
 
High urinary Cd -.112 .692 .894 .515 1.554 
 
Age -.079 .081 .924 .845 1.010 
 
Hypertension .218 .365 1.243 .776 1.992 
 
Low dose aspirin .694 .009 2.001 1.188 3.370 
 Constant 4.297 .206 73.504     
Nagelkerke R2 = 2.8%, 5.5% and 3.3%; Correct case classification = 82.9%, 83.9% and 81.1%. 
 
Table 32. Logistic regression for multiple cause death including cerebrovascular accident 
(CVA) within the total population (N = 1359), and the never smoked (n = 851) and ever 
smoked populations (n = 501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .101 .379 1.107 .883 1.387 
Age .105 .026 1.111 1.013 1.219 
Aspirin .578 .044 1.783 1.015 3.133 
HDLC .018 .031 1.018 1.002 1.035 
 
Prevalent CVA 1.204 .014 3.333 1.278 8.692 
Constant -11.601 .001 <.001   Never Smoked Urinary cadmium .035 .801 1.035 .791 1.355 
 Age .156 .006 1.169 1.046 1.307 
 
BMI .086 .011 1.090 1.020 1.164 
HDLC .029 .005 1.029 1.009 1.050 
 Prevalent CVA 1.185 .083 3.269 .856 12.488 
 Constant -18.336 <.001 <.001   Ever Smoked Urinary cadmium .301 .207 1.351 .846 2.157 
 
Age .027 .760 1.028 .862 1.225 
 
BMI -.135 .044 .874 .767 .997 
 
HDLC -.005 .768 .995 .964 1.028 
 
Prevalent CVA 1.751 .015 5.761 1.399 23.724 
 Constant -.676 .924 .509     
Nagelkerke R2 = 5.4%, 8.2% and 7.9%; Correct case classification = 93.1%, 92.6% and 93.8%. 
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Table 33. Logistic regression for multiple cause death including cerebrovascular accident 
(CVA) within the total population (N = 1359), and the never smoked (n = 851) and ever 
smoked populations (n = 501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .756       
Medium urinary Cd .056 .865 1.058 .554 2.018 
High urinary Cd .223 .483 1.249 .671 2.327 
Age .104 .028 1.110 1.012 1.218 
 
Aspirin .584 .042 1.793 1.021 3.150 
HDLC .018 .031 1.018 1.002 1.035 
 
Prevalent CVA 1.207 .014 3.345 1.278 8.754 
Constant -11.815 .001 <.001   Never Smoked Low urinary Cd  .410     Medium urinary Cd .308 .410 1.361 .653 2.834 
 High urinary Cd -.195 .636 .822 .366 1.850 
 Age .164 .004 1.178 1.054 1.318 
 
BMI .075 .029 1.078 1.008 1.153 
 
Hypertension .707 .044 2.027 1.018 4.038 
 
HDLC .028 .007 1.028 1.007 1.049 
 
Prevalent CVA .847 .229 2.334 .587 9.275 
 
Constant -19.130 <.001 <.001   Ever Smoked Low urinary Cd  .069    
 
Medium urinary Cd -1.206 .168 .300 .054 1.660 
 
High urinary Cd .577 .304 1.780 .593 5.346 
 
Age .018 .843 1.018 .855 1.212 
 
BMI -.129 .054 .879 .771 1.002 
 
Hypertension -.113 .824 .893 .330 2.417 
 
HDLC -.005 .761 .995 .964 1.027 
 
Prevalent CVA 1.924 .013 6.849 1.509 31.094 
 Constant -.560 .937 .571     
Nagelkerke R2 = 5.4%, 5.9% and 5.7%; Correct case classification = 93.1%, 92.7% and 93.8%. 
 
Table 34. Logistic regression for coronary heart disease (CHD) within the total population 
(N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 501), for log 
transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .102 .211 1.107 .944 1.299 
 Hypertension .430 .020 1.538 1.069 2.213 
 Low dose aspirin .479 .019 1.614 1.083 2.406 
 eGFR -.025 <.001 .975 .963 .988 
 
HDLC -.017 .008 .983 .970 .995 
 
Constant .831 .154 2.296   Never Smoked Urinary cadmium .088 .376 1.092 .898 1.328 
 
Low dose aspirin .372 .154 1.451 .869 2.421 
 
eGFR -.025 .004 .976 .959 .992 
 
HDLC -.021 .011 .979 .963 .995 
 
Constant 1.229 .088 3.419   Ever Smoked Urinary cadmium .121 .414 1.129 .844 1.509 
 
Low dose aspirin .755 .022 2.127 1.116 4.052 
 
eGFR -.027 .015 .973 .953 .995 
 
HDLC -.014 .178 .986 .966 1.006 
 Constant 1.117 .230 3.056   
Nagelkerke R2 = 7.4%, 5.7% and 8.4%; Correct case classification = 82.3%, 83.2% and 81.2%. 
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Table 35. Logistic regression for coronary heart disease (CHD) within the total population 
(N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 501), for 
tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .747       
 Medium urinary Cd .117 .600 1.124 .725 1.743 
 High urinary Cd .166 .453 1.180 .766 1.818 
 Hypertension .432 .020 1.540 1.069 2.219 
 
Low dose aspirin .485 .017 1.625 1.090 2.421 
 
eGFR -.025 <.001 .975 .963 .988 
 
HDLC -.017 .008 .983 .970 .996 
 
Constant .550 .351 1.733   Never Smoked Low urinary Cd  .589    
 
Medium urinary Cd .057 .835 1.059 .618 1.814 
 
High urinary Cd .268 .328 1.307 .764 2.237 
 
Low dose aspirin .375 .151 1.455 .872 2.429 
 
eGFR -.025 .005 .976 .959 .992 
 
HDLC -.021 .012 .979 .963 .995 
 
Constant .947 .190 2.578   Ever Smoked Low urinary Cd  .918    
 
Medium urinary Cd .134 .734 1.144 .527 2.481 
 
High urinary Cd .009 .981 1.009 .480 2.123 
 
Low dose aspirin .768 .019 2.155 1.132 4.105 
 
eGFR -.028 .013 .973 .952 .994 
 
HDLC -.014 .173 .986 .966 1.006 
 Constant .927 .340 2.527     
Nagelkerke R2 = 7.2%, 5.7% and 8.2%; Correct case classification = 82.3%, 83.2% and 80.8%. 
 
Table 36. Logistic regression for coronary heart disease (CHD) event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .025 .738 1.025 .886 1.187 
 Age .078 .010 1.081 1.019 1.148 
 Hypertension .560 .001 1.751 1.257 2.439 
 Low dose aspirin .600 .001 1.822 1.261 2.634 
 
eGFR -.029 <.001 .971 .960 .983 
 
HDLC -.015 .010 .985 .974 .996 
 
Constant -4.751 .047 .009   Never Smoked Urinary cadmium -.012 .879 .988 .850 1.149 
 
Age .087 .008 1.091 1.023 1.164 
 
BMI .031 .112 1.031 .993 1.071 
 
Hypertension .483 .010 1.620 1.122 2.340 
 
Low dose aspirin .681 .001 1.976 1.343 2.908 
 
eGFR -.022 .002 .979 .966 .992 
 
Constant -7.674 .005 <.001   Ever Smoked Urinary cadmium .030 .773 1.030 .842 1.261 
 
Age .050 .214 1.051 .972 1.137 
 
BMI .066 .004 1.068 1.022 1.117 
 
Hypertension .304 .181 1.355 .868 2.115 
 
Low dose aspirin .742 .003 2.101 1.285 3.433 
 
eGFR -.023 .005 .977 .962 .993 
 Constant -5.203 .109 .005     
Nagelkerke R2 = 11.8%, 10.1% and 11.0%; Correct case classification = 76.6%, 76.8% and 71.1%. 
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Table 37. Logistic regression for coronary heart disease (CHD) event within the total 
population (N = 1359), and the never smoked (n = 851) and ever smoked populations (n = 
501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .646       
 Medium urinary Cd -.177 .386 .838 .562 1.249 
 High urinary Cd -.028 .887 .972 .659 1.434 
 Age .079 .010 1.082 1.019 1.149 
 
Hypertension .555 .001 1.742 1.249 2.431 
 
Low dose aspirin .603 .001 1.827 1.264 2.641 
 
eGFR -.029 <.001 .971 .959 .983 
 
HDLC -.015 .010 .985 .974 .996 
 
Constant -4.753 .046 .009         
Never Smoked Low urinary Cd  .628    
 
Medium urinary Cd -.088 .679 .916 .604 1.389 
 
High urinary Cd -.212 .335 .809 .525 1.245 
 
Age .089 .007 1.093 1.025 1.166 
 
BMI .031 .106 1.032 .993 1.071 
 
Hypertension .496 .008 1.642 1.136 2.374 
 
Low dose aspirin .677 .001 1.968 1.336 2.897 
 
eGFR -.022 .002 .978 .965 .992 
 
Constant -7.673 .005 <.001         
Ever Smoked Low urinary Cd  .396    
 
Medium urinary Cd .375 .188 1.454 .833 2.540 
 
High urinary Cd .143 .606 1.154 .670 1.987 
 
Age .049 .221 1.050 .971 1.136 
 
BMI .064 .005 1.067 1.020 1.115 
 
Hypertension .332 .146 1.394 .890 2.183 
 
Low dose aspirin .741 .003 2.098 1.283 3.432 
 
eGFR -.023 .005 .978 .962 .993 
 Constant -5.387 .098 .005     
Nagelkerke R2 = 11.9%, 10.2% and 11.5%; Correct case classification = 76.4%, 76.8% and 70.2%. 
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Table 38. Logistic regression for multiple cause death, including coronary heart disease 
(CHD) event within the total population (N = 1359), and the never smoked (n = 851) and 
ever smoked populations (n = 501), for log transformed urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Urinary cadmium .049 .642 1.050 .854 1.291 
Age .162 <.001 1.176 1.082 1.277 
BMI .055 .024 1.056 1.007 1.107 
Hypertension .730 .004 2.076 1.254 3.435 
 
eGFR -.032 <.001 .968 .952 .985 
 
LDLC .007 .012 1.007 1.002 1.012 
 
Prevalent CHD 1.301 <.001 3.673 2.029 6.650 
Constant -15.366 <.001 <.001          
Never Smoked Urinary cadmium .098 .345 1.103 .900 1.350 
 Age .169 <.001 1.184 1.083 1.295 
 Hypertension .598 .026 1.818 1.075 3.075 
 
Low dose aspirin .640 .016 1.896 1.127 3.190 
 
eGFR -.024 .010 .976 .959 .994 
 
Prevalent CHD 1.129 .001 3.093 1.636 5.849 
 
Constant -13.944 <.001 <.001         
Ever Smoked Urinary cadmium -.003 .981 .997 .770 1.291 
 
Age .056 .253 1.058 .961 1.165 
 
Hypertension .140 .620 1.150 .662 1.996 
 
Low dose aspirin .024 .943 1.025 .527 1.993 
 
eGFR -.022 .031 .978 .958 .998 
 
Prevalent CHD 1.429 <.001 4.174 2.003 8.697 
 Constant -4.810 .206 .008     
Nagelkerke R2 = 17.7%, 15.8% and 10.0%; Correct case classification = 89.1%, 89.1%% and 84.2%. 
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Table 39. Logistic regression for multiple cause death, including coronary heart disease 
(CHD) event within the total population (N = 1359), and the never smoked (n = 851) and 
ever smoked populations (n = 501), for tertiles of increasing urinary cadmium 
concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .981       
Medium urinary Cd .006 .983 1.006 .567 1.785 
High urinary Cd .049 .863 1.051 .600 1.840 
Age .162 <.001 1.176 1.082 1.278 
 
BMI .055 .022 1.057 1.008 1.108 
 
Hypertension .730 .005 2.076 1.252 3.441 
 
eGFR -.032 <.001 .968 .952 .985 
LDLC .007 .011 1.007 1.002 1.012 
 
Prevalent CHD 1.297 <.001 3.658 2.020 6.624 
Constant -15.492 <.001 <.001          
Never Smoked Low urinary Cd  .542    
 
Medium urinary Cd .315 .291 1.370 .763 2.457 
 
High urinary Cd .081 .793 1.085 .591 1.990 
 
Age .174 <.001 1.190 1.088 1.302 
 
Hypertension .617 .022 1.852 1.094 3.138 
 
Low dose aspirin .648 .015 1.911 1.135 3.217 
 
eGFR -.023 .015 .977 .960 .995 
 
Prevalent CHD 1.132 <.001 3.103 1.642 5.864 
 
Constant -14.693 <.001 <.001         
Ever Smoked Low urinary Cd  .698    
 
Medium urinary Cd .298 .410 1.347 .664 2.732 
 
High urinary Cd .121 .731 1.129 .565 2.255 
 
Age .056 .254 1.058 .960 1.165 
 
Hypertension .159 .573 1.172 .674 2.038 
 
Low dose aspirin .020 .954 1.020 .525 1.981 
 
eGFR -.022 .033 .978 .959 .998 
 
Prevalent CHD 1.437 <.001 4.209 2.018 8.781 
 Constant -4.963 .194 .007     
Nagelkerke R2 = 17.6%, 15.8% and 10.2%; Correct case classification = 89.1%, 89.1%% and 84.4%. 
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Table 40. Logistic regression for atherosclerotic vascular disease (ASVD) event within the 
total population (N = 1359), and the never smoked (n = 851) and ever smoked populations 
(n = 501), for tertiles of increasing urinary cadmium concentrations. 
    
B Sig. 
Odds 
Ratio 
95% OR 
  
Lower Upper 
Total Population Low urinary Cd   .526       
 Medium urinary Cd .136 .365 1.146 .853 1.539 
 High urinary Cd -.019 .900 .981 .730 1.319 
 Age .103 <.001 1.108 1.059 1.159 
 
BMI .037 .006 1.037 1.011 1.065 
 
Ever smoked .415 .001 1.514 1.181 1.940 
 
Hypertension .608 <.001 1.836 1.433 2.352 
 
Low dose aspirin .573 <.001 1.774 1.328 2.372 
 
eGFR -.016 .001 .984 .975 .994 
 
Constant -8.619 <.001 <.001         
Never Smoked Low urinary Cd  .300    
 
Medium urinary Cd .019 .924 1.019 .689 1.508 
 
High urinary Cd -.272 .186 .762 .508 1.141 
 
Age .110 <.001 1.116 1.050 1.186 
 
Hypertension .744 <.001 2.105 1.503 2.947 
 
Low dose aspirin .500 .011 1.649 1.120 2.426 
 
Cystatin C 1.487 .001 4.426 1.878 10.429 
 
Constant -10.670 <.001 <.001         
Ever Smoked Low urinary Cd  .202    
 
Medium urinary Cd .436 .111 1.546 .905 2.642 
 
High urinary Cd .410 .115 1.507 .905 2.512 
 
Age .033 .397 1.033 .958 1.115 
 
Hypertension .323 .131 1.381 .909 2.099 
 
Low dose aspirin .678 .011 1.971 1.171 3.315 
 
Cystatin C 1.071 .027 2.919 1.128 7.554 
 Constant -4.197 .144 .015     
Nagelkerke R2 = 11.9%, 12.7% and 7.5%; Correct case classification = 64.0%, 64.1% and 61.1%. 
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Table 41. Cox proportional-hazards for time until death within the total population (N = 
1359), and the never smoked (n = 851) and ever smoked populations (n = 501) for observed 
cadmium, without Cystatin C. 
    
B Sig. 
Hazards 
Ratio 
95% HR 
  
Lower Upper 
Total Population Low urinary Cd   .065       
 Medium urinary Cd .098 .380 1.103 .887 1.371 
 High urinary Cd .246 .022 1.279 1.037 1.578 
 Age .088 .000 1.092 1.058 1.127 
 
Ever Smoked .255 .004 1.290 1.084 1.536 
 
Diabetes .441 .004 1.555 1.147 2.108 
 
Hypertension .277 .003 1.319 1.101 1.581 
 
Low dose aspirin .297 .004 1.346 1.101 1.646 
 
Prevalent CVD .315 .001 1.370 1.128 1.664 
      
Never Smoked Low urinary Cd  .632     Medium urinary Cd .111 .419 1.118 .853 1.465 
 
High urinary Cd -.008 .956 .992 .751 1.311 
 
Age .126 .000 1.134 1.089 1.181 
 
Diabetes .563 .006 1.755 1.180 2.611 
 
Hypertension .498 .000 1.646 1.293 2.094 
 
Low dose aspirin .378 .004 1.460 1.129 1.887 
 
Prevalent CVD .124 .343 1.132 .877 1.460 
      
Ever Smoked Low urinary Cd  .001    
 
Medium urinary Cd .133 .483 1.143 .787 1.659 
 
High urinary Cd .556 .001 1.744 1.245 2.445 
Age .045 .076 1.046 .995 1.099 
 
Diabetes .212 .386 1.236 .765 1.996 
 
Hypertension .013 .929 1.013 .768 1.336 
 
Low dose aspirin .167 .313 1.181 .855 1.633 
 
Prevalent CVD .622 .000 1.863 1.377 2.520 
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Appendix C: Kaplan-Meier Plots 
 
Figure 6. Kaplan-Meier plot of time until death between the observed urinary cadmium 
tertiles within the never smoked population (N = 1359). 
 
Figure 7. Kaplan-Meier plot of time until death between the observed urinary cadmium 
tertiles within the never smoked population (N = 1359).   
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Appendix D: Cox Proportional-Hazards Plots 
 
Figure 8 Cox proportional-hazards plot of time until death in the total population and 
presented as observed urinary cadmium. 
 
 
Figure 9. Cox proportional-hazards plot of time until death in the total population and 
presented as tertiles of observed urinary cadmium. 
 
 Association between Cadmium and CVD  
 
81 
 
Figure 10. Cox proportional-hazards plot of time until death within the never smoking 
population and presented as observed urinary cadmium. 
 
 
Figure 11. Cox proportional-hazards plot of time until death within the never smoking 
population and presented as tertiles of observed urinary cadmium. 
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Figure 12. Cox proportional-hazards plot of time until death within the ever smoking 
group and presented as observed urinary cadmium. 
 
 
Figure 13. Cox proportional-hazards plot of time until death within the ever smoking 
group and presented as tertiles of observed urinary cadmium. 
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Appendix E: Urinary Cadmium Concentrations 
Table 42. Urinary cadmium concentrations and demographic information from the 
studies identified in the literature. 
Reference 
Demographics of participants Urinary 
Cadmium 
Concentration 
Population Race N Males 
(%) 
Age 
(yrs) 
Callan, A. C., Devine, A., Qi, L., Ng, J. C., 
& Hinwood, A. L. (2015). Investigation of 
the relationship between low 
environmental exposure to metals and bone 
mineral density, bone resorption and renal 
function. International Journal of Hygiene 
and Environmental Health. doi: 
http://dx.doi.org/10.1016/j.ijheh.2015.03.0
10 
Australian ND 77 0 50-83 Median 
(Range): 0.20 
(<0.065-0.99) 
µg/L. Adjusted 
median (range): 
0.26 (<0.065-
1.03) µg/g 
creatinine 
       
Centres for Disease Control and Prevention 
[CDC]. (2015). The Fourth National 
Report on Human Exposure to 
Environmental Chemicals, Updated 
Report.  Atlanta, GA: CDC. 
NHANES 
(2011-
2012) 
Rep. 2504 ND ≥ 20 Overall GM: 
0.19 µg/L (0.22 
µg/g 
creatinine), GM 
for men (≥6 
yrs): 0.15  µg/L 
(0.14 µg/g 
creatinine), GM 
for women (≥6 
yrs): 0.16 µg/L 
(0.22 µg/g 
creatinine) 
  
    
 
Everett, C. J., & Frithsen, I. L. (2008). 
Association of urinary cadmium and 
myocardial infarction. Environmental 
Research, 106(2), 284-286. doi: 
10.1016/j.envres.2007.10.009 
NHANES 
III 
Rep. 4912 ND 45-79 Mean urinary 
cadmium,  µg/g 
creatinine; 
Never smoker = 
men (0.35), 
women (0.70); 
Former smoker 
= men (0.66), 
women (1.01); 
Current smoker 
= men (1.01), 
women (1.45) 
     
     
     
       
Fagerberg, B., Bergström, G., Borén, J., & 
Barregard, L. (2013). Cadmium exposure, 
intercellular adhesion molecule-1 and 
peripheral artery disease: a cohort and an 
experimental study. British Medical 
Journal 3(3), e002489. doi: 
10.1136/bmjopen-2012-002489 
Swedish ND 489 0 64 GM 0.36 µg/g 
creatinine      
     
     
       
Health Canada. (2010). Report on human 
biomonitoring of environmental chemicals 
in Canada.  Ottawa, Canada: Health 
Canada. 
Canadian Rep. 1083 50.0 60-79 Overall GM: 
0.50 µg/L (0.70 
µg/g 
creatinine), GM 
men: 0.57 µg/L 
(0.60 µg/g 
creatinine), GM 
women: 0.45 
µg/L (0.81 µg/g 
creatinine)  
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Hinwood, A. L., Callan, A. C., 
Ramalingam, M., Boyce, M., Heyworth, J., 
McCafferty, P., & Odland, J. Ø. (2013). 
Cadmium, lead and mercury exposure in 
non smoking pregnant women. 
Environmental research, 126(1), 118-124. 
doi: 10.1016/j.envres.2013.07.005 
Australian 
non-
smoking 
pregnant 
women 
ND 173 0 19-44 Median: 0.66 
µg/L, 0.78 µg/g 
creatinine 
       
Mendy, A., Gasana, J., & Vieira, E. R. 
(2012). Urinary heavy metals and 
associated medical conditions in the US 
adult population. International journal of 
environmental health research, 22(2), 105-
118. doi: 10.1080/09603123.2011.605877 
NHANES 
(2007-
2008) 
Rep. 1857 49.6 ≥ 20 GM: 0.27 µg/g 
creatinine     
    
    
       
Menke, A., Muntner, P., Silbergeld, E. K., 
Platz, E. A., & Guallar, E. (2009). 
Cadmium levels in urine and mortality 
among U.S. adults. Environmental health 
perspectives, 117(2), 190-196. doi: 
10.1289/ehp.11236 
NHANES 
III 
Rep. 13958 ND ≥ 20 GM for men 
0.28 µg/g 
creatinine, for 
women 0.40 
µg/g creatinine 
     
     
       
Navas-Acien, A., Silbergeld, E. K., 
Sharrett, R., Calderon-Aranda, E., Selvin, 
E., & Guallar, E. (2005). Metals in urine 
and peripheral arterial disease. 
Environmental health perspectives, 113(2), 
164-169. doi: 10.1289/ehp.7329 
NHANES 
(1999-
2000) 
Rep. 790 ND ≥ 40 GM: 0.36 µg/L, 
median (IQR) 
of 0.36 (0.19-
0.67) µg/L 
    
    
    
       
Peters, J. L., Perlstein, T. S., Perry, M. J., 
McNeely, E., & Weuve, J. (2010). 
Cadmium exposure in association with 
history of stroke and heart failure. 
Environmental research 110(2), 199-206. 
doi: 10.1016/j.envres.2009.12.004 
NHANES 
(1999-
2006) 
Rep. 12049 ND ≥ 30 GM: 0.30 µg/L 
    
    
    
       
Shirai, S., Suzuki, Y., Yoshinaga, J., & 
Mizumoto, Y. (2010). Maternal exposure 
to low-level heavy metals during 
pregnancy and birth size. Journal of 
Environmental Science and Health, 45(11), 
1468-1474. doi: 
10.1080/10934529.2010.500942 
Japanese 
pregnant 
women 
NA 78 0 22-42 GM: 0.77 µg/g 
creatinine 
       
Sponder, M., Fritzer-Szekeres, M., 
Marculescu, R., Mittlböck, M., Uhl, M., 
Köhler-Vallant, B., & Strametz-Juranek, J. 
(2014). Blood and urine levels of heavy 
metal pollutants in female and male 
patients with coronary artery disease. 
Vascular Health And Risk Management, 
10(1), 311-317. doi: 
10.2147/VHRM.S61510 
Austria ND 164 67.7 ND Overall median 
(IQR): 0.67 
(0.30-1.50) 
µg/L; women: 
0.72 (<0.40-
1.45) µg/L; 
men: 0.65 
(<0.40-1.50) 
µg/L 
     
     
     
     
       
Tellez-Plaza, M., Guallar, E., Fabsitz, R. 
R., Howard, B. V., Umans, J. G., 
Francesconi, K. A., . . . Navas-Acien, A. 
(2013). Cadmium exposure and incident 
peripheral arterial disease. Circulation: 
Cardiovascular Quality and Outcomes, 
6(6), 626-633. doi: 
10.1161/CIRCOUTCOMES.112.000134 
US Strong 
Heart 
Study 
Native 
American 
2864 38.9 45-74 Overall GM:  
0.94 µg/g 
creatinine    
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Tellez-Plaza, M., Guallar, E., Howard, B. 
V., Umans, J. G., Francesconi, K. A., 
Goessler, W., . . . Navas-Acien, A. (2013). 
Cadmium exposure and incident 
cardiovascular disease. Epidemiology, 
24(3), 421-429. doi: 
10.1097/EDE.0b013e31828b0631  
US Strong 
Heart 
Study 
Native 
American 
3348 40.0 45-75 Mdn 0.92 
(0.61-1.45) 
µg/g creatinine, 
GM 0.94 µg/g 
creatinine 
   
   
    
       
Tellez-Plaza, M., Navas-Acien, A., 
Crainiceanu, C. M., Sharrett, A. R., & 
Guallar, E. (2010). Cadmium and 
peripheral arterial disease: gender 
differences in the 1999-2004 US National 
Health and Nutrition Examination Survey. 
American Journal Of Epidemiology, 
172(6), 671-681. doi: 10.1093/aje/kwq172 
NHANES 
(1999-
2004) 
Rep. 6456 51.6 ≥ 40 GM for men: 
GM 0.31 µg/g 
creatinine (0.37 
µg/L); women: 
GM 0.44 µg/g 
creatinine (0.31 
µg/L) 
    
     
     
     
     
       
Tellez-Plaza, M., Navas-Acien, A., Menke, 
A., Crainiceanu, C. M., Pastor-Barriuso, 
R., & Guallar, E. (2012). Cadmium 
exposure and all-cause and cardiovascular 
mortality in the U.S. general population. 
Environmental Health Perspectives, 
120(7), 1017-1022. doi: 
10.1289/ehp.1104352 
NHANES Rep. 8989 ND ≥ 20 Overall GM 
0.28 µg/g 
creatinine, 
women 0.34 
µg/g creatinine, 
men 0.22 µg/g 
creatinine 
       
Rep = representative; GM = geometric mean; NHANES = National Health and Nutrition Examination Survey; ND = 
not defined; NA = not applicable  	  
